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                                                                      ABSTRACT 
 
Background: Angina with normal epicardial coronaries occurs in upto 20% of patients who underwent 
coronary angiogram for angina. Coronary slow flow comprises a separate group among this population 
designed Syndrome Y and accounts for upto 7% of patients undergoing CAG for angina. Coronary slow 
flow is characterized by the delayed passage of contrast injected into the epicardial coronaries. 
Conventionally, coronary slow flow is determined by the coronary filling time. We tried to determine 
whether coronary emptying time is a significant predictor of coronary slow flow 
Methods: We selected consecutive patients, who underwent angiogram for angina and found to have 
normal epicardial coronaries, randomly between the study period November 2011 and November 2012. 
We assessed the coronary filling and emptying times at prespecified standard vascular landmarks on the 
basis of TIMI frame counts 
Results: We analysed the angiograms of 37 patients. 27 patients had LAD slow flow and 17 patients had 
RCA slow flow (10 had normal flow in LAD and 12 had normal flow in RCA).  8 had non dominant 
small RCA and was excluded from the study. We observed positive correlation of coronary filling times 
and emptying times, both in LAD and RCA, in slow flow patients unlike those with normal flow. We 
found the filling times and emptying times are significantly prolonged in slow flow patients (p value 
<0.05) in LAD and RCA. Capillary and venous transit time is prolonged in both LAD and RCA slow 
flow groups, but was significantly prolonged in RCA slow flow patients. (Pvalue <0.05, LAD slow flow 
group, P value 0.43).  We observed slow flow significantly more in male population and significantly 
associated with high LDL/HDL ratios and high triglycerides. 
Conclusion: Coronary emptying time is an independent and significant predictor of Coronary Slow Flow 
Phenomenon. 
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INTRODUCTION 
 
The coronary slow flow phenomenon is a coronary microvascular disorder characterized by the delayed 
passage of contrast, injected into the epicardial coronaries, in the absence of obstructive epicardial 
coronary artery disease. It is well recognized by coronary angiographers but largely has been considered 
an angiographic curiosity and received little attention despite previous studies demonstrating coronary 
microvascular dysfunction.  
The presentation of coronary slow flow phenomenon differs from other  coronary microvascular 
disorders, with most patients undergoing angiography after admission  with an acute coronary syndrome 
accounting for 4% of unstable angina admissions. The clinical course is debilitating, with over 80% of 
patients experiencing recurrent chestpain necessitating readmission to the coronary care unit in almost 
20%(5).  
In  the previous studies CSFP was defined on the basis of angiographically normal or  near  normal 
epicardial coronary arteries and TIMI 2 flow. Conventionally, the dye injected to  the coronaries will 
opacify the distal vascular bed within 3 cardiac cycles(as evidenced by 3 cardiac contractions). If the 
duration is more than that is designated slow flow. TIMI (Thrombolysis In Myocardial Infarction) frame 
count was developed as a simple objective quantitative reproducible method to assess coronary blood 
flow. This method counts the number of cine angiographic frames required for radioopaque contrast to 
reach specified distal landmarks in each coronary artery. 
Cineangiography is performed with 5rF catheters and filming at 30 frames per second. The TIMI frame 
count can further be corrected (CTFC) by normalizing for the length of the LAD for comparison with the 
2 major arteries. Distal landmarks used in analysis are as follows 1. For the LAD, the distal bifurcation of 
the LAD 2. For the circumflex system distal bifurcation of the branch segment with the longest total 
3 
 
distance 3. For the right coronary artery, the first branch of the posterolateral artery. Normal TFC for 
LAD is 36+/- 3; for LCx 22+/-4, for RCA 20+/-3. Each has CTFC of 21+/-2.  
High CTFC may be associated with microvascular dysfunction  despite and open artery where as CTFC < 
20 frames per second are associated with normal microvascular function, low risk for adverse events in 
patients following myocardial infarction. Coronary slow flow is defined by elevated TFC observed in the 
epicardial coronaries. Coronary slow flow is defined by the coronary filling time that is the number of 
frame counts that the contrast takes to travel from the ostium of a coronary artery to the specified distal 
landmark.  
The emptying time of the coronaries are not studied previously though it indirectly determines the flow of 
blood through the coronary microvasculature. Hence we postulated  that coronary emptying time is a 
better predictor of coronary slow flow as compared to the coronary filling time. Coronary filling time is 
more operator dependant but emptying time is an independent variable that determines the ease with 
which the dye flows through the coronary microvasculature. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
Aims 
The primary aim of the study is to determine the epicardial coronary arterial filling time and emptying 
time at prespecified vascular landmarks in patients with chestpain and normal epicardial coronaries and to 
determine whether coronary artery emptying time is a predictor of coronary slow flow phenomenon 
(CSFP).  
 
Objectives 
1. To determine the coronary artery filling time and emptying time at prespecified vascular 
 landmarks in patients with chestpain and normal epicardial coronaries. 
2. To determine the association of coronary arterial filling time and emptying time in patients with 
coronary slow flow phenomenon. 
3. To determine the association of various conventional coronary artery disease risk factors in 
patients with coronary slow flow phenomenon. 
4. To determine the association of coronary artery risk factors with the coronary filling and 
emptying times. 
5. To determine the clinical profile of patients with coronary slow flow phenomenon 
6. To determine the association of various clinical parameters with coronary filling and emptying 
times. 
 
Hypothesis 
The hypothesis we made is that coronary artery emptying time is a significant predictor of coronary slow 
flow phenomenon. 
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REVIEW OF LITERATURE 
 
The Coronary  Slow  Flow  Phenomenon  (CSFP)  is  an  angiographic  observation characterised  by 
delayed passage of contrast in the epicardial vessels during selective coronary  arteriography(2).  This 
is  thought  to  represent  dysfunction  of  the coronary  microcirculation.  Coronary slow flow 
phenomenon is designated Syndrome Y(6). Patients with angina or angina like chest pain and normal 
coronaries is termed Syndrome X. They may represent 10 to 20% of those who undergo coronary 
angiogram  for clinical suspicion of angina(1). Syndrome Y is a different clinical entity compared to 
syndrome X as evidenced by  
 
1. Mechanistic difference between syndrome X and CSFP.  
2. CSFP has typical clinical features as compared to syndrome X.  
3. The prognosis of patients with CSFP is not benign as those with syndrome X.  
 
CSFP  is a known clinical entity for the interventional cardiologists for the past 4 to 5 decades. However 
the pathogenetic mechanisms is not clearly understood yet. CSFP is not just  a clinical curiosity. It has 
significant clinical implications. It has been associated to  clinical manifestations of myocardial 
ischaemia, life threatening arrhythmias, sudden cardiac death and recurrent acute coronary syndromes(7).  
 
This should be differentiated from the delay contrast progression in the context of coronary reperfusion 
therapy like angioplasty or coronary stenting or other secondary causes of coronary slow flow. 
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Conditions associated with secondary coronary slow flow(10-12) 
 
Conditions 
 
Mechanism of slow flow 
Coronary ectasia 
 
Reduced coronary flow velocity 
Coronary spasm 
 
Increased epicardial resistances 
Coronary stenosis 
 
Increased epicardial resistances 
 
Embolism 
 
 
Microvascular plugging 
Heart failure 
 
Increased intracavitary pressure 
Angioplasty and stenting of acute  
 
myocardial infarction 
 
Reperfusion injury, impaired rheology 
Valvular heart disease 
 
Increased left ventricular end diastolic  
 
pressure  
 
Connective tissue disorders Impaired rheology 
 
 
 
ASSESSMENT OF THE CORONARY MICROCIRCULATION 
 
 
 
The study  of  human  coronary  microvasculature  function  is  complicated  by  two fundamental  
problems.  Firstly,  there  is  no  currently  feasible  means  to  directly visualise  the  coronary   
microcirculation  in  vivo.  Secondly,  obtaining  coronary microvessels  for    ex-vivo  or  in-vitro  
analysis  is  methodologically  challenging  and difficult to sustain on ethical grounds. Thus any dynamic 
study of the human coronary microcirculation usually involves a combination of indirect measures of 
microvessel function and/or the use of surrogate vessels, either from other human vascular beds or 
animal models. 
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IN VITRO TECHNIQUES 
 
 
 
In  vitro  experimental  techniques  permit  individual  vasoactive  agents  and  their receptors to be  
studied within the vessel type in question free from neurohumoral influences. Unfortunately, while  
these techniques maximise the analysis of drug- receptor interactions the results obtained are  
difficult to extrapolate to the intact organism. This is circumvented to a degree by the preservation of 
the endothelium in the isolated vessel preparations and the local vascular environment in the perfused 
heart preparation. Despite these caveats the following techniques provide relatively simple and robust 
methods of evaluating microvascular reactivity. 
 
1. Wire Myograph 
2. Pressure Myograph 
3. Isolated perfused heart models 
 
 
IN VIVO TECHNIQUES 
 
 
 
The more an experimental model approaches ‘real world’ physiology the less the number of  
parameters that can be measured and the greater the variation in the measurements.  This  is  due  to  
progressively  more  feedback,  feed  forward  and counter regulatory systems that are present within 
the model. Hence, the quality and detail of experimental data must be balanced against clinical 
relevance. A combined approach is usually adopted whereby individual parameters are analysed in vitro 
and their contribution to overall vascular physiology examined in vivo. Where  possible confounding 
variables are anticipated and minimised. 
 
 
Direct Visualisation – Intravital Microscopy 
 
 
 
Needle-probe videomicroscopy can be used  to directly visualize epicardial, endocardial  and 
intramyocardial  coronary  microvessels in open chested, beating heart, animal  preparations. The 
technique was pioneered by Chilian et al(16)   and involves  positioning  the  microscope  within  the  
relevant  myocardial  territory  and recording vessel calibre in much the same way as the pressure 
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myograph. Pacing and cardiac-cycle synchronised ventilation are required to reduce movement artefact 
and  perturbations   in   myocardial  demand.  Vessel  diameter  can  be  recorded continuously  to  
determine  systolic  to  diastolic  ratios  or  strobascopically  at  end diastole to minimise temporal 
resolution  artefact.  Cannulation of the epicardial coronary vessels allows the infusion of vasoactive 
agents. Changes in small vessel resistance  can  be  verified  by  recording  flow  within  the  large  
feeding  vessels concurrently with small vessel diameter(17). 
 
Indirect Assessment – Coronary Blood Flow 
 
 
The determination of coronary flow remains the cornerstone of human coronary microvascular   
reactivity  assessment.  Coronary  flow  is  a  good  surrogate  for microvascular tone as the  
coronary microvessels are the vascular segments that exert  the  greatest  influence  on  coronary  
vascular  resistance  (in  the  absence  of obstructive large vessel disease). Coronary flow can either be 
measured indirectly in the epicardial vessels or directly within regions of perfused myocardium. Large 
vessel flow  will  always  represent  the  net  result  of  individual  vessel  tone  within  the 
microvasculature.  Substantial  changes  of  tone  within  regions  of  the  microvessel network  may   
not  be  appreciated  if  they  move  in  opposite  directions  (e.g. subendocardial shunting of flow to 
subepicardium). Direct measurement of microvascular flow can overcome this problem but only if it has 
sufficient resolution. 
 
Flow assessment techniques either provide an index of flow or measure absolute flow. Absolute  total 
coronary flow provides little meaningful information because of the large variation in resting 
myocardial demand between individuals. Absolute flow within  each  coronary  vessel  is  even  less  
useful  due  to  the  extreme  individual variability in perfusion territory subtended by each coronary 
artery. Absolute coronary flow must therefore be normalised to myocardial mass for it to be a useful 
measure of resting microvessel tone(18). 
 
In terms  of  the  in  vivo  assessment  of  vasomotor-stimulus  induced  changes  in coronary flow  a  
number  of  flow-modifying  factors  may  operate  concurrently and confound the results. These 
include; (a) transcoronary pressure gradient shifts, due to aortic or right atrial pressure changes, (b) 
transmyocardial pressure gradient shifts, caused by changes in intraventricular pressure, (c) variation 
in myocardial demand caused  by  changes  in  peripheral  resistance,  neurohormones  and  heart  rate  
(d) variation in heart rate causing changes in diastolic perfusion time. 
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Coronary Sinus Thermodilution Technique 
 
 
Coronary blood flow can be estimated by determining flow in the coronary sinus (CS). The 
anatomy of the coronary venous system is such that the coronary sinus drains 75% of total coronary 
flow and 85% of left main coronary flow. The rest returns to the heart via the anterior cardiac vein and 
the thespian veins. If the great cardiac vein is selectively cannulated its flow is closely correlated to 
that of the left anterior descending coronary artery. 
 
The  technique  of  coronary  sinus  thermodilution  was  introduced  in  1971.  The relatively 
demanding technique is less frequently utilized today given its measurement 
limitations (see below) and inability to continuously assess blood flow. Thermodilution uses the same 
principles as other indicator dilution techniques; the greater the dilution of the indicator, in this case – 
saline temperature, the greater the blood flow, because greater blood flow transfers more heat to the 
perfusate. From a practical viewpoint this involves injecting  room temperature saline into the CS at a 
constant rate and temperature via a catheter and accurately recording the increase in downstream 
temperature with a thermistor attached to the same catheter. Absolute flow is calculated using 
empirical data derived from an in vitro model. Subsequent in vivo validation studies have shown it to 
be poorly correlated with coronary flow. For example, it has been demonstrated that a 1cm 
movement of the catheter within the sinus can  cause a threefold change in flow readings and that 
significant catheter movement occurs even  with normal respiration(19,20). This can be exacerbated  
by  increased  right  atrial  pressures  and  CS  reflux.  Furthermore  the technique can be insensitive 
for even moderate changes (< 30%) in  flow; under reporting flow reserve by up to 90% compared 
with doppler flow wire. Its main advantage lies in the ability to perform coronary sinus blood 
sampling (for substrate metabolism) while recording blood flow from the same territory. 
 
Coronary Sinus - Oxygen Saturation 
 
 
Coronary sinus blood flow can be measured by the Fick principle as well as the thermodilution 
technique. The Fick principle states that; flow through tissue has an inverse linear relationship to the 
amount of oxygen extracted from its arterial blood (provided that tissue oxygen consumption  
remains constant). Stated another way; reduced perfusion allows longer for oxygen extraction, 
increased perfusion reduces oxygen extraction. As long as myocardial demand remains stable an index 
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of coronary sinus flow can be calculated by determining the arteriovenous difference in oxygen content. 
As arterial oxygen content is constant, changes in coronary flow will be reflected in changes in CS 
venous oxygen content which is measured by oxygen saturation. 
 
The technique can be performed either by CS catheter insertion and intermittent blood sampling,  or 
the use of catheter tipped oxymeters. The technique is more robust than CS thermodilution but 
suffers similar constraints imposed by measuring the venous outflow(21). CS oxygen saturation is 
often combined with thermodilution to determine the true stimulus causing changes in blood flow. For 
example, a pure vasodilator will increase absolute flow, as calculated by thermodilution, without 
increasing myocardial oxygen consumption  –  resulting  in  a  rise  in  CS   oxygen  saturation.  In  
the  case  of vasodilatation caused by a pure metabolic stimulus, a flow  increase will still be 
recorded by thermodilution but because myocardial consumption is elevated  there will be no 
corresponding increase in CS saturations. 
 
Coronary Artery Thermodilution 
 
 
The  determination  of  a  flow  index  for  individual  coronary  vessels  using  a thermodilution 
technique has only recently been introduced although the      videodensometric 
principle it is based upon was first described in 1967. It has been validated in animal and humans by 
electromagnetic flow probe and doppler flow wire data. Early results indicate that it has the potential 
to be the most accurate method of invasively calculating relative changes in epicardial coronary 
flow(22,23). The technique uses a thermistor/pressure transducer tipped guide wire inserted a 
minimum of  6cm  into the coronary vessel. A bolus of room temperature saline is rapidly injected 
via the guiding catheter and the mean transit time (Tmn) for the saline bolus (and hence coronary 
blood) to  reach the thermistor can be derived from the thermodilution curve. The inverse of Tmn, is 
an index of coronary flow velocity which has a strong linear correlation with absolute coronary blood 
flow.  
 
Invasive Intracoronary Doppler Flowire 
 
Intravascular doppler-tip  devices  can  analyse  the  shift  in  piezoelectric-generated ultrasound   
frequency produced by the movement of red blood cell in the blood stream. The magnitude of the 
Doppler effect is proportional to blood velocity, and the continuous acquisition of doppler-shifted  
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ultrasound frequencies allows phasic and average blood flow velocity to be measured. This is one of 
the few techniques that can measure systolic and diastolic phases of coronary blood flow and  the 
most extensively validated. In common with coronary thermodilution it can measure regional 
coronary flow of each coronary vessel. The piezoelectric guidewire is the only intracoronary doppler 
device currently in use and as it does not need to be deployed a set distance from the guide catheter, 
can interrogate each coronary  artery irrespective of length. A 12MHz crystal creates a fixed pulse-
wave sampling volume which  records blood velocity 5mm distal to the wire end to avoid wire-
generated turbulence(25,26). The  doppler  signal is plotted as a continuous spectral trace 
concurrently with the electrocardiogram. As with coronary-thermodilution determined Tmn, flow-wire 
determined velocity can be used  as  an  index  to  measure  relative  changes  in  coronary  flow  
provided  that changes  in  vessel   crossectional  area  do  not  occur.  Absolute  flow  can  be 
calculated by multiplying the integral  of the spectral velocity trace by quantitative coronary 
angiography / intravascular ultrasound derived vessel area. Furthermore the deceleration slope of the 
diastolic flow signal can provide further information regarding  flow  in  the  microcirculation.  In  
patients  with  ischemic  impairment  of coronary microvascular flow  the  deceleration half time 
(DHT) is substantially and significantly reduced compared to normals. 
 
The  practicalities  of  achieving  a  stable  epicardial  diameter  usually  mean  pre- treatment with 
nitrates which have the potential to alter the microvascular response to the studied vasoactive  agent. 
Conversely, substances active on the coronary microvasculature, also can act on large  epicardial 
segments even if only by flow mediated  vasodilatation.  This  means  that  correct  estimation  of  
vessel  lumen  is essential for most study protocols, and care must be taken to exclude the effects of 
contrast  medium  on  coronary  blood flow  if angiography is employed. The  other drawback  of  the  
technique  is  achieving  a  stable,  transaxial  position  of  the  flow wire. The doppler signal is 
critically dependent on the angle between the crystal and the direction of  coronary flow. This angle 
can change with vessel movement through the cardiac cycle or during intracoronary injections(27). 
 
 
 
Non-invasive Transthoracic Coronary Doppler Techniques 
 
 
It has been possible to measure coronary artery velocity with transthoracic doppler since 1987. 
However it has only become feasible, in most patients, following recent technical  advances  in  
ultrasound  technology  (high-resolution  2-dimensional  and colour flow doppler transducers with 
harmonic imaging). It is currently possible to get doppler data from the LAD in 90% of transthoracic 
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echocardiogram studies as it lies only a few centimetres from the chest wall. The RCA is a deeper 
structure and can only  be  visualised  in  75%  of  cases.  The  circumflex  is  not  amenable   to 
interrogation. It is a non invasive technique, which is inexpensive and repeatable. The benefits are 
tempered by a number of important drawbacks; (a) limited access to all myocardial territories (b) 
velocity data only (not able to assess epicardial disease or epicardial dimensions) (c) moderately high 
inter- and intra-observer variability. As a result it can  only  realistically  provide an index of 
coronary flow  within the  LAD and the confounding effect of changes in LAD diameter cannot be 
excluded(30-32). 
 
TIMI Flow Grade / Corrected TIMI Frame Count 
 
 
The corrected TIMI frame count  technique (CTFC) is variation on the theme of indicator-derived   
coronary  transit  time  (the  same  principle  used  by  coronary thermodilution). It involves 
calculating the number of cine frames (as a measure of time) for angiographic contrast to reach a 
predefined landmark (distance) to derive an  index  of  coronary  velocity  and  hence  flow.  
Angiographic  contrast  has  been validated  as  an  accurate  flow  tracer and  a  correction  factor  has  
been determined to normalise the longer of the left anterior descending  artery length to that of the 
circumflex and right coronary arteries. CTFC is a more quantitative adaptation of the categorical 
TIMI flow grade scheme which was first introduced to assess flow post myocardial infarction in 
1985. TIMI grading utilises cardiac cycles to measure contrast transit as follows; (a) Grade 0, no 
contrast progression (b) Grade 1, contrast progression insufficient to opacify vessel (b) Grade 2, ≥ 3 
cardiac cycles for full coronary opacification (c) Grade 3, < 3 cardiac cycles for coronary opacification. 
This grading scheme,  although normalising flow for heart rate, suffers from poor inter-observer 
agreement, can only determine gross differences in flow and does not correct for vessel length. 
Furthermore, no significant differences in flow exists between grades 1 and 2 as determined by 
doppler flow wire, and a large overlap in velocities exists between grade 2 and 3.The CTFC was 
introduced by Gibson to provide a simple, continuous angiographic  measure of coronary flow 
without the need for excessive intracoronary instrumentation. It has been validated with doppler-
determined coronary flow over a range  of  flow  states  (r2=0.5-0.6) and  discrepancies  appear  to  be  
due  to  cTFC measuring  average  flow  velocity  as  opposed  to  doppler  which  measures  point 
velocity. It is not affected by injection variables (speed, volume or timing). It is however, predictably  
altered  by  changes  in  epicardial  diameter    produced by nitrates. 1-2 minutes must be left 
between injections to allow the brief, contrast- induced vasodilatation of coronary resistance vessels to 
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subside(33-40) 
 
Videodensitometry/Myocardial Blush 
 
 
The assessment of angiographic contrast appearance in the myocardium provides a direct,  semi-
quantitative measure of  microvascular  flow.  Videodensitometry is an offline technique  whereby 
contrast time-density curves are derived in myocardial regions of interest after the epicardial injection 
of radio-opaque contrast. Time from the beginning of ECG triggered contrast injection to the peak of 
the myocardial time- intensity curve is measured usually in cardiac cycles. The myocardial blush grade 
(MBG)   is a simplification of the videodensometric technique and involves subjective grading of 
myocardial contrast appearance (blush) according to the following scale; 0, no myocardial blush; 1, 
minimal myocardial blush; 2, moderate myocardial blush but less than that obtained during 
angiography of a contralateral or ipsilateral coronary artery; and 3, normal myocardial blush or contrast 
density. Given its qualitative  nature MBG, can only provide information of gross regional 
differences in microvascular coronary flow and has relatively poor inter- and intra-observer 
agreement(42-43). Both methods have shown that  discrepancies  exist  between epicardial flow and 
myocardial flow, with myocardial perfusion often being impaired in the presence of normal large 
coronary flow. 
 
 
Echocardiography – Myocardial Contrast 
 
 
Myocardial contrast echocardiography (MCE) offers substantial improvements over the 
videodensitometry techniques as it can measure the regional myocardial blood volume as well as  
microvascular blood velocity   and has sufficient resolution to assess differences in transmural 
perfusion. It is one of only two techniques able to perform frequent, longitudinal assessment of coronary 
flow reserve. MCE utilises gas filled microbubbles that are inert, remain entirely within the vascular 
space,  possess  an intravascular rheology similar to that of red blood cells  and, with a mean 
diameter  of ~4µm, cross the pulmonary capillary bed unrestricted. During  intravenous  infusion  and  
following  the  attainment  of  a  steady  state,  the microbubbles are destroyed with a burst of high 
energy ultrasound within the scan plane.  The  rate  of  myocardial  microbubble  replenishment  is  
measured,  which represents mean red blood cell velocity (β). In the normal resting state the scan 
plane refills within 4 to 5 seconds and at maximal hyperaemia (~ 4 times baseline coronary  flow)  
normal   replenishment  occurs  within  one  second.  At  plateau replenishment myocardial contrast 
intensity represents relative blood volume within the scan plane which can be normalised to the LV 
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cavity signal to give myocardial blood volume fraction (A). This is multiplied by the rate of 
replenishment (velocity or β) to derive an accurate index of myocardial flow - Aβ. The MCE flow 
index is closely correlated with absolute coronary flow and can accurately measure relative changes 
in flow in response to vasoactive agents. Because the capillaries constitute 90% of the myocardial 
vessels and do not respond to vasoactive stimuli, myocardial blood volume does not change between 
high and low flow states unless there  is an epicardial stenosis. In this scenario endocardial arterioles 
beyond the stenosis are maximally  dilated at rest. Epicardial arterioles however, remain partially 
constricted, thereby maintaining pressure within the system and preventing transmyocardial steal. 
With a vasodilatory stimulus the  epicardial arterioles open and effectively depressurise the system 
resulting in capillary collapse (de-recruitment) beginning in the endocardial layers. This results in a 
regional loss of myocardial blood volume and hence ultrasound signal. A reduced contrast signal is 
also seen when imaging infracted / non perfused tissue. Hence, when imaging myocardium subtended 
by normal large coronary vessels A is not required. The main drawback with MCE derived myocardial 
flow is movement artefact. The technique  is   critically  dependent  on  destroying  and  then  
recording  contrast replenishment within the same myocardial scan plane. This is no thicker than 5mm 
and often less than 1mm at the focus. Cardiac translation caused by base to apex shortening and 
rotation results in areas of the myocardium being imaged at different times during the cardiac cycle. 
Respiratory translation compounds the problem. Both can be avoided by ECG triggering and breath 
hold. ECG triggering however reduces the  number  of  data  points  used  for  calculating  the  
replenishment-time  curve, requiring replicate imaging for each area of interest. As a consequence the 
technique is time consuming and lacks sensitivity in difficult to image subjects(44-48). 
 
 
Positron Emission Tomography 
 
 
PET  scanning  remains  the  gold  standard  for  the  non-invasive  assessment  of coronary 
microvascular flow, because flow can be measured absolutely and adjusted for tissue mass, allowing 
valid comparisons between individuals’ resting coronary microvessel tone as well as reactivity. 
Positron emitters are formed when neutrons are added to the nucleus of normal elements resulting 
in nuclear instability and decay. When positrons are released they annihilate on contact with nearby 
electrons to form 2 photons of identical energy that are released in exactly opposite  directions  and can 
be detected by a coincidence circuit within a scanner. By building up positron counts in a 
tomographic fashion, 2 dimensional planes through the ventricle can be reconstructed. Intraventricular 
blood pool counts can also be measured. By determining the amount of myocardial uptake relative to 
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the arterial tracer concentration and using a validated kinetic model, tracer counts can be converted to 
absolute units of flow per minute per gram of tissue. The resolution of the  technique is sufficient for 
the assessment of flow within 480 individual myocardial segments  allowing quantitative assessment 
of microvascular flow heterogeneity. The technique is critically dependent on a positron emitting agent 
that is completely extracted by the myocardium in direct proportion to the local blood flow, and is 
not influenced by myocardial  metabolism. In this regard oxygen-15 labelled water is regarded as 
ideal as it is metabolically inert and freely diffusible. However it produces images of less impressive 
resolution than nitrogen-13  labelled ammonia which is almost as good. Both agents have a limited 
half life which allows  multiple studies over a short period. PET is particularly useful in instances of 
diffuse microvascular impairment(52-53). 
 
MRI-Myocardial Perfusion 
  
An index of myocardial perfusion by MRI has been validated for the quantification of changes in  
transmural blood flow. Early studies suggest that this modality has the greatest resolution of any 
technique yet available. A standardised bolus of gadopentetate dimeglumine is given intravenously by 
power injection followed by rapid image acquisition. Regions of interest are drawn on the Epicardial 
and endocardial short axis images and propagated automatically throughout the 
perfusion series. Curves showing signal intensity plotted against time are constructed for each region of 
interest. Curve fitting is used to obtain the slope of the first-pass contrast enhancement which when 
normalised to the slope within the left ventricular cavity can be used as and index of myocardial  
blood velocity and hence flow. The technique has been validated for large and small   coronary 
disease. 
 
 
Electron beam CT has encouraging data for assessing myocardial blood flow in animal  models.  
EBCT derived coronary flow reserve, in particular shows a strong correlation with doppler  derived 
flow data and may even be able to differentiate arteriole from capillary flow(54,55). 
 
 
ASSESSMENT OF MICROVASCULAR FUNCTION / REACTIVITY 
 
 
 
The assessment of the cardiac microvasculature is usually performed as an adjunct to large vessel 
assessment, be this for the indirect diagnosis of epicardial stenosis or for determination of the  
downstream  effects of epicardial plaque rupture. Consequently  the microvascular vasoactive 
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stimuli  used and validated are predominantly vasodilators (either to provoke regional differences in 
myocardial flow or to reverse impaired microvascular flow). With the emergence of cardiac syndrome x 
as a clinical entity the direct assessment of the coronary microvascular response to endothelium  specific  
agents  and  putative  vasoconstrictors  as  well  as  the  above mentioned vasodilators, has been 
conducted but published data remains limited. 
 
 
Coronary Flow Reserve 
 
 
 
Coronary flow reserve (CFR) is a widely applied method for assessing the human coronary 
microcirculation. It is used primarily in the context of epicardial disease to determine functional 
stenosis severity. It can be performed utilising any technique that  can  quantitate  c o r o n a r y  or   
myocardial  blood  flow  or  velocity.  Validated techniques  include; CS thermodilution, CA 
thermodilution, CA  doppler (intracoronary and   transthoracic), myocardial  contrast  echo, TIMI  
frame count and PET. Intracoronary  doppler is currently the gold standard, however PET provides the 
best resolution. When large vessel stenosis is absent CFR can be used for ‘pure’ assessment  of the 
vasodilator response  of  the coronary microcirculation.  In simple terms, CFR measures the relative 
capacity of   the coronary microvasculature to maximally dilate from a resting level of vasomotor tone. 
In reality a number of  factors other than vasorelaxation determine CFR and include; (a) the level of 
resting vascular tone (b) the perfusion pressure and total crossectional area of the resistance vessels at 
peak vasodilatation (c) the blood viscosity(56,57) 
 
 
Determinants and Limitations of CFR 
 
 
 
As previously stated CFR is designed to assess the vasodilatory capacity of the microvasculature. 
Unfortunately it cannot determine the underlying mechanism of reduced  capacity. A number of 
confounding factors can cause false positive and negative results by either increasing resting blood 
flow or reducing maximal flow. 
 
A.  Resting flow is set by auto regulatory mechanisms as described by Mosher in 1964 and is 
largely determined by myocardial oxygen demand. Any condition that increases myocardial 
metabolism above normal will artefactually reduce CFR; 
• Heart rate: thyrotoxicosis, fever, anaemia 
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• Wall stress: hypertension, heart failure, valvular disease 
• Pre/afterload: hypertension, heart failure, renal failure 
 
B. Reduced  maximal  flow:  maximal  flow  follows  a  steep,  linear  flow-pressure relationship.  
Any  condition,  other  than  an  intrinsic  microvascular  disorder,  that  
            reduces the maximal flow for a given perfusion pressure (i.e. reduces the slope of the  
            flow-pressure relationship) will artefactually reduce CFR. 
• extrinsic compression, (phasic and/or continuous): tachycardia, left ventricular 
hypertrophy, elevated end diastolic pressure. 
• Reduced microvascular crossectional area: infarction, left ventricular  
      hypertrophy (LVH) 
• Increased viscosity: polycythemia. 
 
In reality the main confounders are very rapid tachycardia, elevated ventricular filling pressures and  
LVH (which can be corrected for if ventricular mass is known). The other significant drawback is the 
limited resolution of the flow measuring modalities.Flow is spatially and temporally  heterogeneous 
within the myocardium, particularly between the sub and epicardium(58-60).  
 
 
Endothelial Function 
 
 
Most studies dealing with the endothelial control of vascular tone have examined large conduit  
arteries. Coronary microvascular endothelial vasomotor function has also been evaluated, in a  
limited number of studies, with: (a) acetylcholine, L- arginine, (b) serotonin, (c) atrial natriuretic 
peptide and (d) substance P.  These substances  can  induce  vasodilatation  only  in  the  presence  of  
an  intact endothelium, while their effects may be reduced or even reversed in the presence of 
endothelial impairment. Pacing has also been used to examine endothelium derived, flow mediated 
vasodilatation.  Zeiher  et  al.,  found  that  intracoronary  injection  of  acetylcholine  increased 
myocardial blood up to 140% in normals. In patients with non flow-limiting coronary atherosclerosis,  
however,  the  increase  was  limited  to  12%  (in  the  presence  of preserved  adenosine-derived  
coronary   reserve).  These  findings  document  the possibility of selective alteration of endothelial 
control of microvascular tone.  
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Golino et al., using a similar patient population and techniques,  documented  absolute constriction of 
the microvasculature to serotonin, rather than reduced vasodilatation. A significant correlation in 
patients with cardiac syndrome x, between the threshold for exercise-induced ECG changes and 
reduced acetylcholine-induced intracoronary flow has also been demonstrated.  Although these  studies  
demonstrate  the  endothelium  may  be  important  for  the regulation of coronary microvascular tone 
in certain disease states, the data should be interpreted with caution. For example, it is generally 
accepted that acetylcholine produces  endothelial  mediated  vasodilatation  as  well  as  a  direct  
vasoconstrictor effect on the coronary smooth muscle. However, the net response depends as much on 
the applied dose as endothelial integrity. This is highlighted by vasoconstriction to acetylcholine in the 
presence of vasodilatation to pure endothelial agonists in large vessels. Whether these differences are 
also present   in the coronary microvasculature and the role endothelial impairment plays in 
coronary microvascular disease remains largely unknown(61-66). 
 
 
CLINICAL ASSESSMENT OF MICROVASCULAR DYSFUNCTION  
 
Direct visualisation of the coronary microvessels in the clinical setting is not possible. Nevertheless, by 
simultaneously     assessing    epicardial vessel diameter and  myocardial blood flow/perfusion (directly 
or indirectly) vasoconstriction of coronary microvessels can be assumed when alterations in blood 
flow cannot be explained by changes in large artery calibre. The measurement of alterations in 
cardiomyocyte homeostasis caused by ischaemia is thought to  be  the most clinically relevant 
assessment of impaired microvascular function (in the presence of  normal epicardial vessels). A 
number of research and clinical techniques are available to measure these alterations. 
 
 
Indirect Visualisation 
 
Coronary Angiography 
 
 
 
Direct  evaluation  of  changes  in  vessel  diameter  can  be  obtained  in  man  by quantitative 
angiography or intracoronary echo, however these techniques can only explore epicardial vessels no 
smaller than 0·5–2 mm in diameter. Investigators have inferred that constriction of vessels at the lower 
limit of angiographic resolution may also extend to smaller vessels. In the study of vasoactive drugs, 
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McFadden and co-workers  analysed coronary angiograms  in  patients  before  and  after  the  
intracoronary  injection  of  serotonin. These  authors  noted  that  vasoconstriction,  in  response  to  
serotonin,  was  more marked in distal segments of the arterial tree. Accordingly, they speculated that 
this constriction might also affect the coronary microvasculature. Similar results have been also 
obtained with intracoronary acetylcholine.  A further example is the study by Pupita et al., who 
evaluated patients with proximal epicardial vessel occlusions supplied  distally  by  collateral  
circulation.  In  these  patients,  episodes  of  resting myocardial  ischaemia  were  associated  with  
angiographic  disappearance  of  the collateral vessels(67). 
 
Thus, angiographic studies have been used as indirect evidence of the participation of coronary  
microcirculatory disturbances in the genesis of myocardial ischaemia. However, this technique does 
not provide any insight into the microvascular segment involved  or  the  mechanism  of  the   disorder.   
To  obtain  this  data,  the  use  of angiography  with  methods  able  to  evaluate   regional   
myocardial  perfusion  is necessary. 
 
 
MCE and MRI 
 
MCE is a sensitive technique for qualitatively assessing impaired microvascular flow. Using techniques 
to completely suppress the tissue signal, relative differences in the amount of contrast  (and hence 
perfusion) present within transmural regions and between coronary territories can be assessed. Flash 
destruction of contrast by a high intensity pulse, followed by observation of its relative time to 
reperfuse increases the sensitivity of the technique. MRI uses a similar principle whereby relative 
differences in contrast accumulation between and  within myocardial segments, following 
intravenous administration of contrast are recorded(68). 
 
 
Evaluation of Microvascular Ischaemia 
 
  
In the assessment of coronary microvascular reactivity, ischaemia is seen as a gold standard  end-point  
because,  on  face  value,  it  provides  a  clinically  meaningful measure of abnormalities in vasomotor 
response. Myocardial  ischaemia  develops  whenever  the  flow  of  arterial  blood  through 
constricted or obstructed vessels is inadequate to meet the metabolic needs of the myocardium. There 
is a  characteristic sequence of events that occurs following interruption to the supply of arterial 
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blood. Tissue oxygen tension diminishes due to consumption  of  oxygen  in  its  freely  diffusible  
form  as  well  as  from  stores  of oxymyoglobin. Intracellular respiration shifts from its aerobic (free 
fatty acids) to its anaerobic form (glucose). Adenosine triphosphate (ATP) stores are rapidly depleted, 
causing  adenosine  diphosphate  (ADP),  adenosine  monophosphate  (AMP)  and adenosine to 
accumulate(69). Shortly thereafter, the ischemic region of the myocardium loses  its  ability  to  
maintain  the  negative  resting  membrane  potential.  Depleted supplies of ATP and the competition 
of H+  for Ca+2  cause the cessation of cardiac contraction. Characteristic metabolic changes occur in 
the ischemic tissue, including an accumulation of tissue lactate, H+  ions, phosphate, and potassium. 
There is also a rise in tissue tension of carbon dioxide (PCO2). Mitochondrial calcium increases as 
well, which may contribute to ischemic akinesis. If myocardial reperfusion is rapidly re-established, 
however, cellular function can return to near baseline levels. Irreversible damage to mitochondria and 
cell membranes causes the release into blood of  numerous plasma markers, which can be used to 
quantify the degree of myocardial necrosis.  Markers of cardiac myocyte death appear in the plasma 
as plasma membrane integrity is compromised; these include enzymes such as lactate dehydrogenase 
(LDH), creatine  phosphokinase (CK), serum glutamic oxaloacetic transaminase  (sGOT),  and  other  
intracellular  proteins,  such  as  myoglobin  and troponin T and I. Ischemic perturbations  in  myocyte  
homeostasis  can  be  detected  by  the  ECG, myocardial  scintigraphy, echocardiography and 
sampling for ischemic metabolites. Reduced perfusion can be detected by the techniques already 
described. 
 
ECG 
 
 
The ECG is the most frequently used technique to detect ischaemia. Reuptake of potassium is  
reduced and the formation of lactic acid increased during ischaemia resulting in reduction in 
amplitude and duration of the action potential and a reduction in  the  resting  membrane  potential.  
This  produces  potential  difference  between normal and ischemic myocardium following  
repolarisation resulting in a ‘current of injury’ and depression of the ST segment. ST  segmental  shifts  
are  however  not  specific  for  ischaemia     and  regional impairment of potassium handling in    
the absence  of ischaemia has been demonstrated to produce false positive results particularly 
during exercise(70-73). 
 
Echocardiography 
 
 
Impaired wall motion is a relatively late manifestation of myocardial ischaemia and is caused by 
homogeneous ischaemia of large regional myocardial segments. Hence  echocardiographic  assessment  
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of wall motion is specific but not sensitive particularly if there is patchy ischaemia in multiple coronary 
territories(74). 
 
Myocardial Scintigraphy 
 
Scintigraphic assessment  of ischaemia involves imaging the distribution of radionuclide tracer within 
the myocardium following metabolic uptake. Thallium (201Tl) is a gamma emitting potassium analogue 
which is both passively and actively (via the sodium/potassium ATPase pump) taken up by myocytes. 
It has high first pass metabolism and there is a linear relationship between blood flow and 201Tl 
accumulation. The agent demonstrates washout from normal tissue and wash in to ischemic tissue 
over time. 
 
99mTechnetium labelled Sestamibi and Tetrofosmin are the most frequently used gamma emitting 
agents. After administration they are trapped within the mitochondria during  first  pass   circulation.  
Mitochondrial  uptake  is  a  function  of  myocardial perfusion to viable tissue. Although these gamma 
emitting scintigraphic agents require non-ischemic tissue for uptake  their   strength  resides  in  their  
ability  to  detect  regional  differences  in myocardial blood flow. Perfusion defects however 
commonly occur in the absence of ischaemia. False positive results may also occur due to soft tissue 
attenuation. 
 
Positron emitting agents overcome this lack of specificity for ischaemia by tracing differences in  
metabolite utilisation. During ischaemia oxidative phosphorylation of fatty  acids  ceases  and  
anaerobic  metabolism  of  glucose  occurs.  Using  positron emitting  analogues  of  glucose  and  free  
fatty  acids,  areas  of  ischaemia  can  be specifically imaged. 
 
MRI Spectroscopy 
 
 
Is a sensitive method of identifying ischaemia pioneered by Bottomley et al(75)   It involves 
defining the intrathoracic volume containing the heart and then acquiring the radiofrequency signal 
particular to 31-phosphorous from within the volume. Phosphorous contained within different molecules 
produces different peaks along the spectral trace. Ischaemia causes a fall in phosphocreatine relative to 
ATP which has been validated in patients with large and small vessel coronary disease. The main 
problem with the technique is its inability to localise the site of ischaemia within the myocardium and 
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not being able to include the posterior wall in the sample volume in all patients(75,76). 
 
 
Biomarkers of Myocardial Ischaemia 
 
 
Metabolic markers for ischaemia can be divided into those that occur as a direct result of  ischaemia 
and those that occur as a consequence of ischaemia-induced infarction. Myocardial  lactate  
production  has  traditionally  been  the  gold  standard  for  the detection of ischaemia. Lactate 
production is the result of anaerobic metabolism of glucose.  Lactate,  when  present  in  arterial  
plasma,  is  used  by  the  non-ischemic myocardium as an energy substrate.  Hence in the normal 
situation there is net transmyocardial lactate extraction. However, reduced lactate extraction can be due 
to inhibition of lactate uptake by free fatty acids as well as ischaemia. Hence, this test, although 
specific, has poor sensitivity due to heterogeneous lactate production and consumption both within 
and between myocardial regions in addition to the regional limitations imposed by CS sampling. pH 
measurement from the CS, is a simple technique to indirectly measure lactate and is able to  provide 
continuous data, however it does not overcome the above limitations and is less specific for 
ischaemia. Ischaemia-modified albumin (IMA) is a new biomarker that is highly sensitive for 
ischaemia in preliminary studies. The discovery that albumin, in the serum of patients with myocardial 
ischaemia, exhibited lower metal-binding capacity for cobalt than the albumin in serum of normal 
subjects was  made by Bar-Or et al. In sera from patients with ischaemia, less cobalt is bound by the 
IMA, leaving more free cobalt to react with an indicator. Significant changes in albumin-cobalt 
binding occur minutes after transient ischaemia and return to baseline within 12 h. IMA is the 
result of reactive oxygen species (ROS) modifying albumin within the coronary circulation. ROS 
are produced when ischaemia activates the oxidative mitochondrial respiratory chain and endothelial 
xanthine oxidase. IMA has a high negative predictive power for ischaemia in the clinical setting, but is 
not specific for cardiac ischaemia or cardiac region of ischaemia. Furthermore, whether this test is 
sufficiently sensitive to detect small zones of ischaemia associated with small vessel disease is 
unknown. Lipid peroxidation products are also generated by the actions of reactive oxygen species 
which occur as a result of myocardial ischaemia. Current data would suggest that they are the most  
accurate  ischemic markers yet found. Rapid and sustained elevations occur following brief large 
vessel occlusion and they are also elevated in active coronary microvascular disease. However CS 
sampling is required as well as sophisticated and prolonged chromographic analysis which limits the 
use of the technique(77,78). 
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Biomarkers of infarction are released following loss in membrane integrity. Troponin and creatine 
kinase are the most thoroughly validated. Troponin has largely replaced CK due to its higher  
sensitivity to smaller myocardial injury and its virtually total specificity for cardiac damage.  
Despite  the ability to detect quantitatively smaller degrees of myocardial necrosis, cardiac troponins 
need 4–10 h after symptom onset to  appear  in  serum,  and  remain  elevated  for   prolonged  periods,  
making  the determination of ongoing myocardial damage difficult. The main  drawback of both 
markers is their complete lack of specificity for the aetiology of myocardial injury. 
 
 
THE CORONARY SLOW FLOW PHENOMENON 
 
 
The coronary  slow  flow  phenomenon  (CSFP)  has  been  defined  as  a  coronary microvascular   
disorder  characterised  by  the  delayed  passage  of  angiographic contrast in the absence of 
obstructive epicardial coronary disease. It is observed in 1% to 7% of unselected patients undergoing 
angiography, 40% (3,4) in the subgroup of patients with angiographically normal arteries and in 16% 
of those meeting the diagnosis for Coronary Syndrome X. In those having angiography for rapid 
assessment of unstable angina (UAP) it is evident in 4% of patients (30% of UAP patients without 
obstructive epicardial  disease)(79,80). It  is  a  separate  entity  from  no-reflow  (even  though  the 
angiographic appearance may be similar) which is  predominantly observed in the setting  of  
primary  angioplasty  following  prolonged  thrombotic   occlusion  of  an epicardial vessel. It has  
variably  been  labelled  as  ‘slow  coronary  flow’,  ‘slow  flow  velocity’,  slow coronary run  off’  and 
‘slow dye progression’ since its first description in 1972 by Tambe et al. In Thrombolysis In 
Myocardial Infarction III A (TIMI IIIA) study,  among  patients presenting with unstable angina, 
4% had normal coronaries with impaired coronary filling suggestive of CSFP. Mangieri et al 
reported 7% incidence of the phenomenon in patients suspected to have CAD.  
 
Method of Assessment  
 
In a similar manner to blood pressure measurement, coronary flow velocity appears to  exist  along  
a  bell  shaped  continuum.  The  cut-off  velocity  for categorical definitions of CSFP is entirely 
arbitrary, and includes:- (a) TIMI grade 2 or less flow (b) Corrected  TIMI frame count (CTFC) 
above normal mean value (21 frames) (c) cTFC of 1 or more, or 2 or more standard deviations 
above normal (24, 27 frames respectively)(2). CSFP was initially assessed subjectively by visual 
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judgement. TIMI flow grade classification is a semiquantitative assessment of coronary blood flow. This 
grading system reflects the speed and completeness of passage of the contrast through the coronary tree. 
This is a widely used method of grading of coronary flow. It has been a valuable tool for comparison of 
flow data in clinical trials. But variability in the visual assessments limits its broad clinical applicability. 
This is a qualitative method of assessing coronary flow. It is limited by significant inter observer 
variability. Conventionally, the contrast injected to the coronary arteries opacifies the distal vascular bed 
within 3 cardiac cycles (evidenced objectively by 3 cardiac contractions). This is prolonged in coronary 
slow flow phenomenon(2). 
 
 
TIMI FLOW GRADES 
TIMI 3 – Normal distal run off – Contrast flows briskly into the distal distal segment and clears 
rapidly. 
TIMI 2 – Good distal run off – Contrast material opacifies the distal bed but slowly. Contrast clears 
slowly from the distal bed as compared with a comparable segment of another vessel. 
TIMI 1 – Poor distal run off – Portion of contrast material reaches the distal bed but distal bed is not 
opacified fully. 
TIMI 0 – Absence if distal run off – No contrast material reaches the distal bed. 
 
 
In contrast CTFC (corrected TIMI frame count) provides an objective and quantitative index of coronary 
fow. It facilitates the standardization of TIMI flow grades and flow assessment. It represents the number 
of cine frames the contrast injected into the coronaries takes to travel from the proximal to distal vascular 
bed. CSFP is defined as CTFC greater than 2 standard deviations from the normal published range for 
that particular vessel. CTFC is a more quantitative and reproducible index of coronary artery flow.  
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Distal landmarks used commonly in the analysis are as follows  
1. The distal bifurcation for the left anterior descending artery(LAD).  
2. Distal bifurcation of the branch segments with the longest distance for the left circumflex 
artery(LCx).  
3. The first branch of posterolateral artery for the right coronary artery.  
 
The corrected TIMI frame count is obtained by normalizing for the length of the LAD as compared with 
the other 2 arteries. CTFC accounts for the distance the dye has to travel in the LAD relative to the 
arteries. The length of LAD, LCx and RCA on an average are 14.7, 9.3 and 9.8 respectively. CTFC 
divides the absolute frame count in LAD by 1.7. TFC(TIMI frame cont) for LAD, LCx and RCA are 
36+/-3, 22+/-4 and 20+/-3 respectively. Each has CTFC of 21+/-2. High CTFC is associated with 
microvascular dysfunction. CTFCs of <20 frames are associated with normal microvascular function. 
Gibson et al and Kern et al suggested visual estimates of TIMI flow bear little relationship to the 
quantitative TIMI frame count. Injection techniques can also impact on the CTFC. Using 7F diagnostic 
catheters, mean increase of 1mL/s of hand injection  can induce a reduction of 2 frames in the CTFC.  
 
As can be seen, the TIMI flow grade definitions of coronary slow flow are set at a substantially  
higher flow velocity threshold than the TIMI frame count definitions. Using published data,  
approximately 43% of CTFC defined slow flow patients would not meet the TIMI grade 2 slow 
flow definition and would also be unlikely to meet the original qualitative definition of slow flow as 
described by Tambe(83). It should be appreciated that a very wide range exists for normal resting 
volumetric flow and that this is even greater for flow velocity due to the added variable of vessel 
calibre. Hence to achieve adequate specificity for those with ‘truly’ reduced coronary flow, a flow 
velocity threshold must be set well below the accepted normal value.  
 
The TIMI 2 definition meets  these criteria and is supported by validated outcome data albeit from 
reperfusion trials. Limited data suggests an inverse correlation between flow velocity and chest pain 
symptoms.  Consequently patients  defined  by  lower velocity  thresholds may be quite different to 
those selected by a higher cut-off. By using CTFC as a quantitative index of coronary flow, coronary 
angiography is the only tool for the diagnosis and assessment of CSFP. This method does not permit 
long-term clinical follow-up and dynamic treatment evaluation of CSFP due to the invasiveness of 
coronary angiography. Transthoracic Doppler echocardiography (TTDE) have enabled the non-invasive 
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demonstration of coronary flow patterns in the left anterior descending (LAD) coronary artery. 
Measurement of coronary flow in the distal LAD using TTDE technique with a high success rate 
(92.3%). Patients with CSFP exhibited lower coronary diastolic velocities of LAD, which was negatively 
correlated with CTFC. TTDE may provide a useful tool for the monitoring of treatment effect and long-
term follow-up for CSFP. However, there is a lack of confirmation in clinical trials, and there is need for 
further evaluation of TTDE in the diagnosis of CSFP(84-90). 
 
 
 
CLINICAL FEATURES 
 
 
 
Demographics  
 
Tambe  et  al   first  described  the  CSFP  when  he  reported  the  clinical  and haemodynamic 
features of 6 cases in 1972. Most had chest pain that was consistent with  stable  or   unstable  
angina,  but  no  history  of  other  cardiac  disease  or cardiovascular  risk  factors.  A  number  
of  case  series  have  subsequently  been published and  have  consistently  shown  the  
phenomenon  to  occur  in  a  unique demographic group. Patients with the CSFP are characterised 
by:- 
• Preponderance of middle aged males. In the largest series, 79% of the study 
population was  male  with  a  mean  age  of  52  years.  In  other  trials  the proportion  of  
males range from 47 to 88%  with average ages between 48 and 57. 
 
• Most have mixed pattern angina  with many (30 – 94%)  experiencing symptoms  
   indistinguishable from unstable angina. Only a small proportion primarily exhibit 
     symptoms of stable angina. 
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• Ongoing  chest  pain  symptoms  despite  treatment  with  many  undergoing 
repeat invasive and non invasive investigations. 
 
 
Only one large case control series has been published comparing the CSFP group to patients also  
lacking obstructive coronary disease but with normal flow velocity. The results were consistent 
with the above data but new findings emerged:- 
 
• Patients with the CSFP were younger, more likely to be male, frequently had      
      multiple coronary risk factors and were often active cigarette smokers. 
• Typically, patients with the CSFP were more likely to present with acute onset rest/mixed  
pattern  angina  and  an  abnormal  ECG,  prompting  emergency admission and rapid  
angiographic assessment. This is consistent with the findings from the TIMI IIIA trial   
which demonstrated the CSFP in a high proportion of patients with non obstructive 
coronary disease presenting with unstable angina. 
• The control group, in contrast, usually presented with chronic exertional chest pain, a 
positive stress test and underwent angiography on an elective basis. Half met the criteria 
for CSFP(91-97). 
 
 
Clinical Manifestations 
 
 
 
Coronary slow flow phenomenon is a frequent angiographic observation with a reported incidence of 1% 
to 7% in patients undergoing diagnostic coronary angiography for angina. CSFP occurs commonly in 
young men and smokers. CSFP may present at times with features suggestive of acute coronary 
syndrome. Clinical course is variable. Upto 80% of patients experience recurrence of chest pain; may be 
occurring at rest. Upto 20% of patients necessitates admission to coronary care units. CSFP has been 
described to be associated with life threatening arrhythmias and sudden cardiac death. Arrhythmic 
potential of CSFP is probably contributed to by the increased QTc dispersion in these patients. Yilmaz et 
al delineated clinical and laboratory features of CSFP.  Metabolic syndrome was more frequent in CSFP 
in the presence of high total cholesterol, high low density cholesterol, high fasting blood glucose levels 
and high body mass index. These data are in line with the observations that insulin resistance states and 
impaired glucose tolerance correlate with CSFP occurrence. These data suggest a common pathogenic 
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mechanism for CSFP and metabolic syndrome. The underlying pathology in both is probably endothelial 
dysfunction.  
 
 
Non Invasive Investigations 
  
 
ECG/Exercise Stress Findings 
 
 
Controlled data suggests that those with the CSFP are significantly more likely to have resting  non-
diagnostic ST/T wave changes (49 vs. 21%). Other studies have reported a wide range in  both  the 
type and prevalence of ECG changes at rest, including episodes of non sustained  ventricular 
tachycardia   and increased QT Dispersion  which may indicate low grade myocardial ischaemia. 
During spontaneous episodes of chest pain, ECG changes consistent with ischaemia are found in  
approximately 30% CSFP patients and are present in all those who subsequently have evidence of 
infarction. In terms of inducible ECG changes with exercise stress, reports vary widely form none  to 
all. In the larger series, half or less of  
 
CSFP patients tested had an ECG positive for ischaemia. When compared to a control group there was a 
trend for CSFP patients to have less exercise induced ECG changes (20 vs.39%, p=0.07) in a study by 
Beltrame et al. 
 
 
SPECT Scintigraphy 
 
 
Two studies  have  specifically  examined  CSFP  patients  with  myocardial  SPECT scintigraphy. 
Ciavolella et al  performed exercise radionuclide ventriculography and perfusion studies in 21  patients 
with the CSFP. The 99mTc-sestamibi scintigraphic studies showed abnormalities in regional wall 
motion in 81% patients and perfusion defects in 86% patients with 76% patients having abnormalities 
in both parameters. 70% of these defects occurred in area supplied by vessels affected by the CSFP. 
Ceasar et al  studied 17 slow flow patients and revealed thallium defects in 76%  with  a  92%  
concordance  between  perfusion  defects  and  coronary  slow  flow territories. Other studies that 
have looked at scintigraphic perfusion report reversible changes in between 26 to 84% of patients. 
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Echocardiography 
 
 
 
Most studies  report  normal  findings.  Beltrame  et  al  found  no  evidence  of  left ventricular 
disease in over 90% of a 64 patient CSFP cohort. Small numbers of slow flow patients do, however, 
show evidence of LVH, dilated cardiomyopathy, diastolic impairment of left ventricular filling and  
resting regional wall motion abnormalities consistent  with  previous  infarction  (despite  normal   
coronary  vessels).  Stress echocardiography has not been studied in this group. 
 
 
Infarction Biomarkers 
 
 
 
Little data exists regarding release of myocardial biomarkers associated with the CSFP. Beltrame et 
al. have reported CK rise consistent with infarction in 6% of CSFP patients compared to  no rise in the 
control population. In observational series an infarction rate of 8 to 9% has been reported. 
 
 
Coronary Angiography  
 
 
Early investigators systematically excluded artefact induced by the contrast injection process as a 
potential cause of the phenomenon. No appreciable difference in the phenomenon was observed  
despite changing the operator, the catheters and the injection amount, velocity and timing. 
Perturbations in perfusion pressure at the time  of  the  phenomenon  were  also  excluded.  Subsequent  
research  on  healthy normal subjects, has shown that contrast progression is independent of catheter 
size, injection velocity/amount and shows <5% increase in transit time if injected in systole compared to 
diastole. In most studies, the left anterior descending and circumflex arteries are the most and least 
affected vessels, respectively, despite their common origin from the left main coronary artery, which 
provides further evidence against the condition being an angiographic artefact. The strongest 
evidence against the phenomenon being an artifact or a haemodynamic aberration is provided 
by a controlled angiographic study by Beltrame et al. Using a  standardised technique, performed by 
the same operator they were unable to demonstrate differences in left ventricular function, large 
vessel diameter, heart rate or blood pressure between the CSFP and control groups(3). 
 
Depending on the definition between 60 to 100% of coronary vessels demonstrate slow flow in any 
given CSFP patient.  Most studies exclude coronary ectasia as it has been shown to reduce coronary 
velocity in the presence of normal coronary flow. Even if all  vessels with slow flow are included, 
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angiographically smooth  contoured  vessels  are  found  in  74%  of  patients, suggesting  that  the 
phenomenon is not a condition of excess large vessel capacitance or deformity in the majority. 
 
Beltrame et al. have studied the persistence of the phenomenon over time and its relationship to 
anginal symptoms. In 12 CSFP patients, angiography was initially conducted during or immediately 
after periods of significant chest pain. Angiography was then repeated when the patients were 
asymptomatic and revealed that only 30% of patients continued to meet criteria for slow flow, 
implying an association between flow rate and symptomatic status. However, compared to controls, 
angiographic flow velocity  in  the  non-TIMI  2  vessels  was  still  significantly  reduced,  suggestive  
of chronically abnormal coronary flow with a dynamic  component. Persistence of the phenomenon at 
time points up to 10 years apart has been demonstrated indicating a chronic process. 
 
 
IVUS 
 
Cin et al.  have published unblinded but controlled data regarding the intravascular ultrasound 
characteristics of the epicardial vessels in patients with the CSFP. They demonstrated that  
intima media thickness of patients with the CSFP was twice that of the control group (p< 0.001), even 
though both groups were well matched in terms of cardiovascular risk factors. This observation was 
diffusely present and was frequently associated  with  confluent  or  discrete  calcification.  There  was  
a  strong  inverse correlation between intima media thickness and coronary flow velocity. 
 
 
Prognosis 
 
 
 
The long term clinical course of these patients was first examined by Ciavolella et al  who asked 21 
CSFP patients to complete questionnaires after a mean follow-up period of 91±44  months. During this 
period, no patient had experienced a major cardiac event but over 50% described their symptoms as 
unchanged or deteriorating. Although this study portends a good prognosis from a cardiac event 
perspective, at least  one  case  report    describes  a  patient  presenting  with  an  anterolateral 
myocardial infarct. 
 
Beltrame et al followed 64 patients for a median period of 21 months. During this period  84%  
continued  to  experience  chest  pain  with  a  third  presenting  to  the emergency department because 
of severe pain and 29% required admission to the coronary  care  unit.  Although  there  were  no  
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myocardial  infarctions,  two  deaths occurred in the follow up period. One patient died in hospital of 
non-cardiac causes but a second died suddenly from an apparent coronary event. Voelker et al  followed 
angiographically normal patients with chest pain, both with and without  the CSFP, for 9 years and 
showed that 81% of slow flow patients (compared with 46% of normal flow patients) continued to 
experience angina. 
 
HISTOPATHOLOGY  
 
 
Mosseri et al  undertook right ventricular endomyocardial biopsies in 6 patients with documented  CSFP.  
These  demonstrated  histologically  abnormal  small  coronary arteries with fibromuscular hyperplasia, 
medial hypertrophy, myointimal proliferation and  endothelial  degeneration.  Electron  microscopy  of  
these  specimens  showed degenerative foci in most  myofibrils with lipofuscin deposits. The most 
consistent finding  in  the  specimens  was  endothelial  swelling  and  degeneration  resulting  in luminal 
narrowing. Further histopathology data was produced by Mangieri et al  who performed left 
ventricular endomyocardial biopsies on 10 patients with CSFP. These investigators also  found  
histological  evidence  of  small  vessel  wall  thickening  with  associated luminal narrowing, dilated 
interstitial  spaces filled with granular fibrillar material. Of note, the disease involvement appeared to 
be patchy  with specimens showing co- existing  normal  and  pathological  zones.  Likewise,  electron  
microscopy  showed patchy involvement,  myofibrillar  disarray  being  present  to  some  extent  in  
most specimens.  Other  findings  included  reduced  cellular  glycogen  content,  swollen 
mitochondria with disrupted cristae, and endothelial cell disruption and thickening. In summary, these 
two studies both suggest evidence of non-specific ‘fixed’ small vessel pathology. Whether these 
morphological abnormalities are a consequence or a cause of the CSFP and how much they represent 
sampling artefact requires further clarification. 
 
PATHOPHYSIOLOGY 
 
 
Investigation of pathophysiology of the phenomenon has proceeded along similar lines to that of 
CSX and variant angina. CSFP patients have reduced coronary flow velocity,  predominantly  in   the  
absence  of  large  vessel  abnormality,  systemic haemodynamic impairment or myocardial disease. 
This combination of features is an accepted surrogate for increased microvessel  resistance.  The 
episodic nature of ischemic manifestations (often at rest) in the CSFP group combined with the lack 
of exercise ischaemia, suggests a disorder of vasomotor hyper-reactivity as also seen in variant angina. 
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Initial pathophysiology investigations were designed to (a) confirm the presence of increased coronary 
microvascular resistance (b) calculate the vasodilator reserve (c) assess the action of vasomotor stimuli 
in this patient group. 
 
 
H aemodynamics 
 
 
Evaluation of microvascular dysfunction was first performed by Mangieri et al who observed  
normalisation of contrast opacification rate in 6 patients with the CSFP following intravenous 
dipyridamole. In contrast, intracoronary GTN administered to all 10 study patents had no impact on 
opacification rate. A similar finding was made by Kurtoglu et al  following 30 days of oral 
dipyridamole treatment (normalisation of angiographic flow in 70 of 75 CSFP vessels). These findings 
of CSFP resolution with a small coronary vasodilator are entirely consistent with the presumed 
microvascular site of the disorder. A controlled haemodynamic trial was subsequently performed with 
12 subjects in each group. All participants underwent coronary sinus catheterisation. Parameters of 
coronary flow where measured in the resting state and during vasomotor stimuli (rapid atrial pacing, 
cold pressor testing and intracoronary acetylcholine infusion). 
 
 
Resting haemodynamics 
 
 
 
Resting coronary sinus flows were lower and a coronary resistance higher in the CSFP  group   than  
the  control  group  despite  similar  myocardial  demand  as determined by the rate pressure 
product. This was supported by significantly lower coronary  oxygen  saturations  in  the  CSFP  
patients,  also  a  marker  of  reduced coronary flow. 
 
Coronary Flow Reserve 
 
CFR to  a  pacing  stimulus  revealed  no  difference  between  CSFP  patients  and controls in  terms 
of peak coronary sinus flow or coronary resistance despite both groups achieving similar peak 
haemodynamic measures. This would suggest normal vasodilator reserve in the CSFP group, albeit from 
a lower baseline. 
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Vasomotor Stimuli 
  
 
(a)Cold  pressor  testing;  resulted  in  variable  responses  in  coronary  resistance between  subjects 
with no consistent outcomes for the group. Several patients did, however, experienced chest pain and a 
substantial increase in coronary resistance to this sympathetic stimulus. 
 
(b)Acetylcholine  infusion;  using  a  similar  protocol  for  the  assessment  of  large coronary spasm, 
produced no overall changes in haemodynamic parameters for the group  but  there  was  a  large  
degree  of  individual  variability,  suggesting  that  a subgroup of the CSFP population may be 
susceptible to this form of provocation. Of interest ACh infusion did not induce large vessel spasm  
in any patient effectively excluding dynamic epicardial disease as a potential contributing factor in the 
disease. 
 
 
Transmyocardial Biomarkers 
 
 
As part of the above study  transmyocardial lactate gradients were measured. Rapid  
atrial pacing produced chest pain in 50% of CSFP patients but only 2 showed ECG changes and none  
exhibited lactate production. Maximal coronary blood flow was  similar  to  controls.  Hence  there  
was  no  metabolic  evidence  of  significant ischaemia, which was consistent with their normal 
vasodilatory response and normal maximal blood flow to metabolic stimuli. Yaymaci et al   also 
studied pacing induced changes in transmyocardial lactate gradients in 34 CSFP patients. Net lactate 
production was observed in 17% of their group and was always  accompanied by chest pain and 
ischemic ECG changes. However without a control group in this study it is difficult to determine 
how specific for the CSFP these findings were and whether they were an artefact of the testing 
process. 
 
Endothelial Function 
 
 
Coronary endothelial function has never been studied directly. Sezgin et al  have measured  flow-
mediated brachial artery dilation in a controlled trial of 27 CSFP subjects. They were careful to 
exclude cardiovascular risk factors in both groups and were able to demonstrate brachial vasodilatation 
in the CSFP patients was 3 times lower than the control group (p<0.001). There was a weak linear 
correlation between coronary flow velocity and brachial artery dilation. 
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PATHOGENESIS 
 
 
Small vessel disease 
The coronary circulation is traditionally considered as a two compartment model. The first compartment 
consists of epicardial vessels  are also referred to as “conductance vessels”, because they do not pose any 
resistance to blood flow. The second compartment consists of “small vessels” of <400 µm known as 
resistive vessels which primarily regulate myocardial blood flow in the absence of any significant 
obstructive epicardial stenosis . Small vessel dysfunction has been typically involved in the pathogenesis 
of CSFP since its first description. Confirming this hypothesis, investigators  reported fibromuscular 
hyperplasia, medial hypertrophy, myointimal proliferation, as well as endothelial edema, thickening and 
degeneration in the coronary microvessels.  Mangieri et al. found thickening of vessel walls with  
luminal size reduction, mitochondrial abnormalities, and glycogen content reduction in left ventricular 
endomyocardial biopsies in CSFP patients. Subsequently, Beltrame et al. indicated  
that CSFP was associated with a chronically elevated resting coronary microvascular tone characterized 
by low coronary sinus oxygen saturation as well as blunted responses to endothelial stimuli such as cold 
pressor or acetylcholine testing. Based on these data, it can be suggested that a combination of structural 
and functional abnormalities coexists in the coronary microcirculation. 
 
 
Endothelial dysfunction 
A growing body of evidence has suggested that the endothelium plays an integral role in the regulation of 
vascular tone, platelet activity, leukocyte adhesion, vascular smooth muscle proliferation, and is 
intimately involved in the development of atherosclerosis. It has been reported that reduced endothelium 
dependent flow-mediated dilatation (FMD) of the brachial artery was detected in patients with CSFP, 
suggesting that endothelial dysfunction is implicated in etiology of CSFP. Noteworthy is the recent 
finding demonstrating that baseline and peak exercise endothelin-1 plasma concentrations were higher 
and nitric oxide plasma concentrations were lower in slow coronary flow patients. In addition, patients 
with slow coronary flow had raised level of plasma homocysteine  and asymmetric dimethylarginine , a 
nitric oxide synthase inhibitor, both of which have a detrimental effect on endothelial function. More 
recently, decreased adiponectin concentrations  and paraoxonase activity, two significant markers of 
endothelial dysfunction have also been shown to be responsible for the etiopathogenesis of CSFP. 
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Subclinical atherosclerosis 
Utilizing IVUS technique and flow rate measurements, Cin et al.  demonstrated that patients with CSFP 
have diffuse intimal thickening, widespread calcification along the coronary vessel wall, and non-
obstructive atheromatous coronary changes. In line with these results, Pekdemir et al. showed that most 
patients with CSFP have longitudinally extended massive calcification throughout the epicardial coronary 
arteries. These data are evidence that CSFP may reflect diffuse, non-obstructive atherosclerotic disease of 
epicardial vessels together with microvascular disease. These findings are supported by previous IVUS 
study indicating that diffuse atherosclerosis is often present in angiographically normal coronary arteries. 
Inflammation 
Inflammation is a contributing factor to several cardiovascular conditions and inflammatory mechanisms 
have also been observed in the context of CSFP. Li et al. showed that the plasma concentration of high-
sensitivity C-reactive protein and interleukin-6 was increased in CSFP patients. Similarly, coronary slow 
flow was associated with higher levels of plasma soluble adhesion molecules, including intercellular 
adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin .  
Other inflammatory markers, such as red cell distribution width and serum uric acid levels, were also 
shown to be correlated with CSFP occurrence . Collectively, abnormalities in inflammatory parameters 
might be an indicator of endothelial dysfunction, both of which contribute to coronary slow flow. 
 
Anatomic factors 
Blood flow patterns in epicardial coronary arteries depend on the geometry and motion of these vessels . 
Disturbed laminar blood flow occurs in arterial segments with geometric irregularities such as curvatures, 
branches, and bifurcations . It is in these complex regions that low blood velocity rates tend to occur. 
Confirming this theory, recent observation with multidetector CT coronary angiography demonstrated 
that in patients with CSFP, the angulations of the main coronary arteries from the aorta were smaller 
determined. Based on this theory, we recently performed a case-control study to explore the correlation 
between anatomic properties of coronary arteries and CSFP occurrence.  
The results showed that the presence of CSFP was associated with higher tortuosity and more distal 
branches in coronary arteries. Accordingly, it is reasonable to assume that certain anatomic properties of 
coronary arteries could be predisposing to disturbed coronary flow and endothelial damage, ultimately 
leading to CSFP occurrence(97-99). 
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MANAGEMENT 
 
Despite good prognosis of CSFP patients, the subsequent progress is frequently characterized by 
remitting, relapsing anginal episodes resulting in considerable impairment in quality of life. 
Unfortunately, currently available anti-anginal agents are of limited clinical value. To date, no large trial 
testing pharmacological approaches has been conducted, and the evidence available derives from small 
studies with inhomogeneous inclusion criteria. It was shown that dipyridamole and mibefradil, which 
both influence functional obstruction in arteries <200 µm, normalized CTFC but nitroglycerine, which 
dilates arteries with diameters >200 µm, did not. Importantly, statins appear beneficial for patients with 
CSFP, likely in part due to their anti-inflammatory properties. More recently, several studies 
demonstrated that nebivolol can both improve endothelial function and markedly ameliorate symptoms, 
thereby improving quality of life in patients with CSFP. Besides its beta-receptor blocking activity, 
nebivolol can cause endothelium-dependent vasodilatation through increased nitric oxide release. On June 
8, 1998, Roche announced the voluntary withdrawal of the drug from the market, due to the potential for 
drug interactions, some of them serious, which may occur when it is taken together with some other 
medications(3,98)). 
 
CONCLUSION 
 
 
 
CSFP is an important, angiographic finding typically observed in patients presenting with  
acute coronary syndrome, in particular unstable angina. This phenomenon should be considered a 
separate clinical entity with peculiar characteristics, pathogenic mechanisms, and defined diagnostic 
criteria. Previous studies have shown that small vessel disease, endothelial dysfunction, subclinical 
atherosclerosis, inflammation, and anatomic properties of coronary arteries are are related to the 
occurrence of CSFP.  
 
Current findings support the hypothesis that CSFP may be part of systemic vascular disturbance. 
Despite relatively few publications the picture of a unique coronary microvascular disease process is 
beginning to emerge, identifiable by its characteristic angiographic appearance – the coronary slow flow 
phenomenon.The disorder has a number of distinctive features; it predominately affects middle aged  
male  smokers  and  causes  episodes  anginal  pain  frequently  at  rest  and frequently  severe  enough  
to  prompt  emergency  treatment.  Ischemic  ECG  and scintigraphic evidence of ischaemia is  
variably present and appears to depend on symptomatic status. Inducible ischaemia in the absence of 
resting symptoms is often difficult  to  demonstrate  despite  frequent  non-specific  ECG   
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abnormalities,  and increased QT dispersion. Although infarction, left ventricular impairment (ischemic 
or  otherwise)  and  sudden  death  are  uncommon,  the  morbidity  resulting  from recurrent chest  
pain is high, partly because conventional antianginal treatment is ineffective. 
 
At angiography  the  CSFP  is  present  in  10%  of  patients  with  normal  epicardial vessels. It is 
most commonly seen in two or more coronaries, with the left anterior descending coronary artery 
most commonly affected even when corrected for length. Non  obstructive  coronary  disease  or  ectasia  
are  infrequent  associated  features. Artefact as a cause of the phenomenon has been  investigated and 
excluded. The phenomenon is most frequently seen during assessment of  unstable angina and 
resolves in most patients when asymptomatic. The phenomenon is caused by increased coronary 
resistance at the level of the microvasculature  which  is  present  even  when  asymptomatic.  In  a  
proportion  of patients, coronary resistance can increase further with the use of vasomotor stimuli. 
Small vessel vasodilators can abolish the phenomenon. Coronary vasodilator reserve is intact to pacing 
stimulus in asymptomatic individuals. The overall clinical picture is consistent with a disorder of 
coronary microvascular tone resulting in episodes of microvessel constriction sufficient to cause 
ischaemia. 
 
When quiescent the vasodilator response is intact implying the periodic occurrence of an unidentified 
vasoconstrictor stimulus. The pathophysiology of the CSFP has received little 
attention. Although histopathology studies imply an element of fixed microvascular structural 
disease, this  seems  to   be  a  minor  component  given  the  results  of  vasodilator  and 
angiographic  follow  up  studies   which  have  shown  a  predominantly  dynamic disturbance of 
coronary resistance. Vasomotor reactivity studies, although positive in a  small  number  of patients 
(predominantly  to sympathetic  stimulation),  show no consistent  response  across  the  group.  More  
recently  impairment  of  endothelial function  has  been  indirectly  implicated.  Early  and  extensive  
intima  and  media disease of the epicardial vessels appears to be a feature of the disease, although its 
significance remains unclear. Our current understanding is incomplete, but clinicians should be aware of 
this condition and its clinical significance. Further experimental investigations are needed to reveal the 
pathogenesis involved in CSFP. In addition, large-scale clinical studies are warranted to better 
characterize these phenomenon, and most importantly, investigate potential therapeutic approaches. 
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CHEST PAIN AND THE NORMAL CORONARY ANGIOGRAM 
 SYNDROME X AND MICROVASCULAR ANGINA 
 
Patients with  unexplained  anginal  symptoms  are  not  uncommon.  Of  those  with symptoms  
suggestive  of  typical  angina  10  to  30%  will  have  normal  coronary angiography. The early  
investigation and characterisation of patients with chest pain and angiographically normal 
coronary arteries was conducted independently by Kemp and Cannon, each working form a different 
perspective of the condition. 
 
Definition 
 
 
Kemp coined the term Cardiac Syndrome X (CSX) in 1973(126)  after defining a patient group  
using   predominantly  clinical  criteria;   
1.   exertional  chest  pain  with  an objectively  positive  stress  test   
2.   absence  of  functional  or  structural  epicardial disease  
3.  absence of valve disease and conditions known to impair microvascular structure/function.  
Cannon took a more mechanistic approach  and used the term ‘microvascular angina’ to describe 
patients with undifferentiated angina and normal angiography who demonstrated an abnormal 
coronary flow reserve to pacing which could be  exaggerated with the use of ergonovine. The 
definitions however do not describe the same patient  population as only 41% of CSX patients 
have reduced coronary flow reserve   and only 10%  of  microvascular angina patients have a 
positive exercise ECG. In addition the microvascular angina definition includes a pre 
cardiomyopathic group particularly if combined with left bundle branch block . 
 
 
Unfortunately there are no uniform definitions for patients with chest pain and normal angiography; 
hence there is considerable heterogeneity between studies. At present the terms ‘cardiac syndrome 
X’ and ‘chest pain with normal coronary angiogram’ are the most common terms for this group  
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and  are used interchangeably. The term microvascular angina is used less frequently and is  
currently a short hand way of referring to impaired vasodilator reserve(127,128). 
 
Clinical Features 
 
 
 
Those with CSX share similar characteristics across a number of studies; 
 
• Higher prevalence of women who are often peri or postmenopausal 
 
• More episodes of painful ST segment depression on ambulatory monitoring compared to 
those with epicardial disease. 
• Prolonged episodes of chest pain without evidence of LV impairment. 
 
• Rapid increase in rate pressure product early in stress testing with angina experienced  at  
a  greater  cardiac  workload  that  those  with  large  vessel 
disease. 
 
• Half have a poor response to nitrates with some experiencing a paradoxical exacerbation 
of chest pain to nitrate therapy. 
• Ongoing symptoms in the majority resulting in chronic disability, repeated 
 
investigations and prolonged, often ineffective, medical therapy. 
 
 
 
Mechanisms 
 
CSX appears to be the end result of two abnormalities, usually with both contributing variably  to   
the   chest  pain  syndrome  within  the  same  patient:  (a)  coronary microvascular dysfunction 
(b) increased pain sensitivity. 
 
 
Microvascular Dysfunction and Ischaemia 
 
Abnormal vasodilator  reserve  is  a  common  finding  in  CSX  and is  present  to endothelium 
dependent and independent stimuli, irrespective of how coronary flow is measured. Abnormal  
coronary  hyper-reactivity  to  vasoconstrictor  stimuli  (cold pressor, hyperventilation, neuropeptide  
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Y,  ergonovine and acetylcholine) has also been  demonstrated  in  subgroups  of  these  patients.  
Consistent  with  this, scintigraphic perfusion defects  and PET derived flow heterogeneity  are 
present in the majority of patients. 
 
 
 
The documentation of ischaemia using coronary sinus sampling, however, has been difficult to 
demonstrate consistently until the recent introduction of sensitive markers. Early studies of 
transmyocardial lactate, pH and oxygen saturations were negative in the majority of patients despite 
pacing induced chest pain and ECG changes. This was congruent with the absence of wall motion 
abnormalities during ECG and chest pain positive stress echocardiography(129,130). 
 
 
The more recent  investigation of these patients with  phosphorous-31 MR 
spectroscopy, a highly sensitive metabolic marker of ischaemia, again demonstrated 
ischemic changes in only 20% of patients. In this study, however, handgrip exertion did not 
invoke ECG changes. In a study involving adenosine and MRI assessment of myocardial 
perfusion reserve, syndrome x patients were shown to have significantly reduced subendocardial 
blood flow during stress compared with  normal  controls.  More  recently  the  use  of  
transmyocardial  lipid  peroxidation  product  sampling  combined  with  pacing  was  able  to  
demonstrate  evidence  of ischaemia in all CSX patients but was absent in all controls. This is the 
first study to unequivocally demonstrate ischaemia in this patient population. 
 
The presence of abnormal coronary vasomotion combined with significant chest pain symptoms and  
a small  ischemic burden (insufficient to cause significant metabolic/functional  impairment or 
excess mortality) is best explained by a patchy transmural  distribution of  inappropriate pre-
arteriolar constriction or reduced vasodilation. In  this   hypothesis, impaired arteriolar 
vasodilatation  during pharmacologic or physiologic stress results in(131): 
(a) heterogeneous myocardial blood flow distribution with an overall reduction in CFR 
(b) transmyocardial and intramyocardial steal and capillary de-recruitment at the end of 
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the most constricted vessels causing small areas of ischaemia and sustained increase in 
adenosine liberation to limit ischaemia. 
(c) Normal  or  increased  flow  through  unaffected  vessels  diluting  ischemic metabolites 
and preventing ischemic impairment of myocardial function 
(d) ST segment changes and anginal chest pain in the absence of ischaemia caused by 
excess adenosine acting on A1 receptors. These receptors are present in perivascular  
afferent nerves and ventricular myocytes. Excess stimulation results in nocioception as  
well as ECG changes (caused by shortening of the action potential). 
 
The aetiology of microvascular dysfunction in CSX has not been fully elucidated. The reduced  
vasodilatory response that characterises the syndrome appears to be a common endpoint of a 
number of pathological processes:- 
1. Structural  abnormalities;  mainly  consisting  of  medial  hypertrophy  and/or fibrosis of 
arteriolar vessels, frequently associated with systemic hypertension, have been 
described in small series of patients. 
2. Endothelial  dysfunction;  is  suggested  by  a  decreased  coronary  flow 
response to endothelium mediated vasodilator stimuli   and could be caused by 
impaired nitric oxide (NO) release and/or activity. Decreased NO generation, as  
determined  by lower nitrate/nitrite systemic concentrations may be present, although  a 
normal coronary cGMP release profile is present in CSX patients. An increased 
synthesis of asymmetric dimethyl arginine, (known to reduce the bioavailability of L-
arginine for NO synthesis in endothelial cells), may contribute to impaired NO activity in 
CSX. 
 
3. Primary smooth muscle cell abnormality; also may be present, as shown by impairment 
of  coronary microvascular dilation in response to endothelium independent stimuli 
(adenosine, dipyridamole, and papaverine)(132-134). 
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4. Altered  potassium  handling;  as  demonstrated  by  increased  exercise 
 
induced  hyperkalemia   in  some  CSX  patients  may  account  for  the increased 
vasoreactivity (as well as ST segment changes and chest pain in the absence of 
ischaemia). 
5. Oestrogen deficiency: oestrogen has vasodilatory properties, its deficiency is a 
recognised cause of endothelial impairment and the majority of female patients with 
CSX  are post menopausal. Replacement therapy reduces symptoms and improves 
exercise tolerance in these patients which suggest that oestrogen deficiency may 
contribute to the microvascular dysfunction in CSX. 
6. Elevated sympathetic tone; resulting in increased microvascular resistance is  suggested          
 
        by  higher  stress  induced  and  ambulatory  heart  rates, hyperdynamic LV response to  
        
       stress  and a response in some patients to α adrenoceptor antagonism. 
7. Inappropriate   vasoconstriction;  increased plasma concentrations of 
endothelin-1 (ET-1) have been found in peripheral blood of CSX patients and correlate 
with coronary microvascular dysfunction. ET-1 increases in the coronary 
circulation of CSX patients in response to atrial pacing.  CSX patients may be more 
susceptible to the vasoconstricting effects of the sympathetic cotransmitter  
neuropeptide y. 
 
8. Enhanced sodium–hydrogen exchanger activity; is consistently observed in CSX  and  
represents a potential cause of microvascular dysfunction by inducing cellular 
alkalinisation and hence, increased susceptibility to smooth muscle  constrictor  stimuli.   
Furthermore,  enhanced  Na+–H+     exchanger activity might be involved in several 
other typical features of CSX, including increased  insulin  resistance  (associated  with   
endothelial  dysfunction), altered adrenergic activity and enhanced pain perception. 
9. Increased  rho-kinase  activity; may enhance vasoconstriction in 
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microvascular smooth muscle cells by facilitating calcium overload, in a similar 
manner to large vessel constriction in variant angina. 
10. Low grade inflammation;  Recent studies have shown increased markers of inflammation 
in CSX patients, compared to matched healthy controls. A correlation between C 
reactive protein values, clinical and electrocardiographic indices of disease activity 
has been found in patients with angina and normal coronary arteries(135-139). 
 
   Pain Sensitivity 
 
 
Several studies  have  consistently  shown  that  patients  with  angina  and  normal coronary 
arteries exhibit enhanced pain perception to both cardiac and other stimuli. These patients are 
more likely  to  have  severe  prolonged anginal pain, reduced tolerance to  forearm ischaemia, 
develop pain with (usually innocuous) right sided catheter manipulation and  respond to 
imipramine (an antidepressant with visceral pain relieving properties). 
 
The high level of psychological morbidity sustained by CSX patients, particularly anxiety   
disorders,  almost  certainly  contributes  to  the  enhanced  perception  of symptoms. There is 
debate regarding whether psychological distress is a primary or secondary manifestation of the 
disorder(140,141). 
The reasons for enhanced pain perception remain elusive. Adenosine and potassium may be 
important, as already mentioned. More recently enhanced cortical activation during  pain,  
compared  to  controls,  has  been  observed.  This  may  be  due  to transmission of afferent 
signals to the cortical pain area which are usually blocked at subcortical level. In addition there 
appears to be a failure for syndrome x patients to habituate to painful stimuli. Abnormality in 
afferent nerve conduction associated with abnormal autonomic function or elevated ET-1 seen in 
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syndrome x patients may play a role. 
 
 
Integration of Pathologic Mechanisms 
 
 
The interplay between microvascular dysfunction and enhanced pain perception will determine  the   
individual  patient’s  clinical  presentation.  A  patient  with  greatly increased pain sensitivity 
may  develop symptoms purely in response to algogenic cardiac (and/or non cardiac) stimuli. 
Patients with highly dysfunctional microvascular function may develop chest pain on the basis of 
ischaemia alone, in the presence of normal pain perception. Those patients with both elements are 
likely to  be  highly symptomatic  and  represent  the  subgroup  in  which  ischemic  indices  are  
usually positive. The elements may also interact such that frequent low grade ischaemia may sensitise  
afferent  pathways to clinically insignificant painful stimuli or abnormal neural function could 
contribute to abnormal microvascular function. 
 
Overall the condition primarily represents a chronic pain syndrome, and as there is no excess  
mortality, management strategies are directed at symptoms rather than surrogate markers of 
ischaemia. 
 
 
Management 
 
 
Due to the multitude of pathophysiologic mechanisms responsible for CSX there is no one 
treatment strategy that suits all patients. Most approaches are based on identifying the most likely 
mechanism and tailoring therapy accordingly: 
1. Beta Blockers and Calcium Channel Antagonists: Useful when ischaemia can be documented 
and where sympathetic overactivity is present 
2. Hormone Replacement: is a proven therapy in post menopausal CSX patients but must be 
balanced against the small risk of major cardiovascular events 
3. Analgesics: Imipramine, electrical nerve and cord stimulation all offer benefit particularly in 
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those with debilitating symptoms 
4. Lifestyle Modifications: physical training, cardiovascular risk facor modification and 
cognitive behavioural therapy all have intuitive appeal but lack objective data 
 
THE NO-REFLOW PHENOMENON 
 
 
 
Definition 
 
 
The no-reflow phenomenon  was  first  described  in  an animal model of  coronary occlusion  
followed  by  reperfusion  by  Kloner  et  al  in  1974(100). Despite  an  open epicardial vessel flow 
within the infarcted regions of myocardium remained impeded. Myocardial flow was traced  
anatomically using dye entrapment. The phenomenon has become increasingly recognised in  
human hearts with the advent of routine percutaneous coronary intervention (PCI) for the  
treatment  of myocardial infarction and elective revascularisation. It is currently clinically 
diagnosed by TIMI grade 0-2 flow within a coronary vessel   or reduced MCE microbubble 
enhancement  of  a coronary territory, in the context reperfusion. 
 
Pathophysiology 
 
 
In the  original  animal  model  description,  no  reflow  zones  were  confined  to  the irretrievably 
damaged myocardium and the area of no reflow approximated the infarct size. Loss of perfusion 
was  due to progressive microvascular occlusion caused by cellular plugging, tissue oedema and 
ischemic contracture. It was not the result of microvessel destruction or loss of the microvascular 
network, which remained largely intact. No-reflow only became apparent after 90minutes of 
occlusion. It started in the endocardium, where blood flow is the most tenuous and spread to the 
epicardium in a time-dependent wavefront. 
 
 
In the clinical setting reperfusion primarily occurs following ruptured atheroma and occlusive  
thrombus. Plaque contents and thrombus may embolise to the coronary microvasculature. Hence, 
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the eventual no reflow zone is usually a combination of ischemic necrosis, reperfusion injury and 
distal embolisation which are unable to be differentiated antemortem. 
 
In the setting of elective PCI, no-reflow primarily occurs in vessels with a large 
atherothrombotic  burden  and  is  thought  to  be  the  result  of  distal  embolisation, possibly 
combined with an element of reperfusion injury. 
 
 
The no reflow zone can only be fully appreciated by imaging myocardial perfusion at the tissue  
level. Angiographic dye progression (TIMI flow grade) is used as a surrogate for no-reflow and 
although specific is insensitive and cannot determine the extent of the no-reflow zone. Consequently 
the phenomenon remains under reported(101-103). 
 
 
 
 
Reperfusion injury 
 
 
Reperfusion of coronary flow post acute myocardial infarction (AMI) is necessary to resuscitate 
ischemic and hypoxic myocardium. This may however result  in paradoxical myocardial  
impairment  or  death,  called  reperfusion  injury     and contributes to the no-reflow 
phenomenon. The myocardium is tolerant of ischaemia for up to 15 minutes without death or 
functional impairment. This situation occurs frequently  during  stable  angina,   epicardial  
vasospasm  and  elective  coronary angioplasty. With increasing periods of ischaemia subsequent 
reperfusion results in progressive  myocyte  dysfunction  which  takes  time  to  resolve.  The  zones  
most affected also contain cells that are irreversibly damaged. 
 
 
 
Myocardial stunning is the most studied manifestation of reperfusion injury. Global or regional 
myocardial tissue which is subject to prolonged ischaemia will often remain hypocontractile for 
long periods despite adequate blood supply. This is thought to be caused by ongoing anaerobic 
metabolism as a result of prolonged inhibition of  mitochondrial pyruvate dehydrogenase, as well 
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as repair of non lethal cell injury. Blood flow,  although restored remains low due to reduced 
cellular requirements acting via autoregulation mechanisms(104-107). 
 
 
 
The microvascular endothelium is the cellular component most likely to be impaired by the 
restoration of normal epicardial flow and the tissue layer most likely to cause no-reflow  following  
reperfusion.  Reperfusion  results  in  substantial  endothelial dysfunction, largely due to ischaemia-
induced changes in mitochondrial function and the  build  up  of  xanthine  oxidase.   With  the  
reintroduction  of  oxygen  these respiratory  chain  enzyme  systems  begin  to  produce  large  
amounts  of  reactive oxygen species which overwhelm the innate tissue antioxidant capacity, in 
particular NO. As a result the usual antithrombotic, anti inflammatory, vasorelaxant properties of  
the  endothelium  are  lost  and  platelet  and  neutrophil  adhesion  molecules  are expressed on the 
endothelial cell surface. The subsequent cellular infiltrate results in the release of  vasoconstrictors,  
more ROS and proteolytic enzymes. Combined with  the  physical  plugging  effects  of  cell  
adhesion,  the  increased  expression  of endothelin, and positive feedback caused by release of 
platelet activating factor, the end  result  is  impaired  tissue  perfusion  which  contributes  to  
ongoing  or  even worsening tissue ischaemia. If the endothelium is already  functionally 
impaired, even brief periods of ischaemia are thought capable of causing no-reflow. The  
physical plugging effects may be overstated as the application of vasodilators is often effective at 
reversing the phenomenon. At the extreme end of reperfusion injury is contraction band necrosis. 
This is caused by reperfusion induced calcium reentry resulting in massive myofibril contraction 
and death.  This  is  due  to  increased  myofibril  calcium  sensitivity,  increased  calcium channel 
transit and impaired sarcoplasmic calcium cycling, coupled with calcium dependent protease 
activation(108-112). 
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Microembolisation 
 
The latter stages of large vessel atherosclerotic plaque development are 
characterised by the formation of a positive-remodelled lipid core with a thin fibrous cap and a 
tendency to ulcerate, haemorrhage or rupture when inflamed by monocyte infiltration or subject to  
percutaneous intervention. These plaques cycle through periodic rupture and repair phases, often 
concurrently, and the development of an acute coronary syndrome or biomarker evidence of  
myocyte infarction is closely correlated with the overall atherothrombotic plaque burden. When 
rupture occurs or is induced, plaque and vessel wall constituents, including lipid, subendothelial 
matrix and platelet thrombus can embolise resulting in microvascular obstruction,  loss of 
endothelial   integrity,   release of vasoactive amines and increased microvascular tone. If this 
of sufficient magnitude, no-reflow occurs and is usually accompanied by infarction(113-115). 
 
 
 
 
There is increasing evidence that microvascular embolism plays an important role in the 
development of ischaemia, and cardiac related mortality in those with epicardial vessel disease. In  
the setting of rapidly reperfused infarction (and hence reduced likelihood of reperfusion injury), 
microvascular occlusion is not infrequent, thought to be secondary to microembolism and is an  
independent predictor of mortality. In those with delayed reperfusion ‘classic’ no-reflow may  
occur at the necrotic core while  embolic  no-reflow  may  occur  in  the  surrounding  tissue  as   
emboli  are preferentially shunted to the relatively well perfused penumbra and increase the zone of 
infarction. Microembolism is ubiquitous in the setting of elective PCI and  
results in microinfarction  in  30  to  40%  of  cases.  Periprocedural  no-reflow  and  
myocardial infarction  is  independently  predicted  by  atheroma  burden  and  invasiveness  of 
revascularisation technique  i.e. factors associated with distal embolisation(116-119). 
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Diagnosis 
  
 
The diagnosis of no-reflow can be suspected when there is increased ST elevation and  
haemodynamic compromise post reperfusion. The original technique for the diagnosis of  no-
reflow  was the TIMI flow  grade.  This  however  is  an insensitive measure and misses up to 
25% of instances post MI. Subsequently doppler flow wire characteristics of no-reflow were  
defined  and  include; rapid  deceleration  of diastolic blood flow and prominent systolic  reversal.  
Scintigraphy and contrast enhanced MRI have also been used, predominantly in the research setting. 
 
 
 
MCE appears to be the most clinically useful and accurate measure of no-reflow zones  post  MI. 
Unfortunately,  due  to  post  reperfusion  hyperaemia,  MCE  will underestimate  no-reflow  if   
performed  within  the  first  48  hrs  of  reperfusion. Thereafter it accurately determines the  no-
reflow area, the size of which predicts subsequent cardiac failure, arrhythmias and post MI 
mortality(120-122). 
 
 
 
 
Management 
 
 
The aims of management are twofold; (a) when ‘classic’ no-reflow predominates and microvessel  
occlusion  is  confined  to  the  area  of  necrosis,  re-establishment  of microvascular flow 
encourages healing, reduces remodelling and promotes collateral circulation. (b) when micro  
embolisation causes no-reflow its amelioration may reduce the infarct zone and infarct expansion. 
The strategies  that  have  benefit  include  (a)  primary  preventive  measures;  early infarct 
reperfusion using primary angioplasty  and glycoprotein IIb/IIIa inhibitors (b) secondary  
preventive  measures;  verapamil   and adenosine   both reduce vasospasm.  Intra-aortic   balloon  
pumping  and  inotropic  support   are  effective particularly when there is evidence of 
haemodynamic compromise(123,124). 
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MATERIALS  AND  METHODS 
 
Study design 
 
This is an observational study of patients with normal epicardial coronary arteries who underwent 
coronary angiogram for angina. The coronary filling and emptying times at predetermined standard 
vascular landmarks were determined. The various coronary risk factors and clinical parameters were 
determined in the study population and their association with the coronary filling and emptying times 
were also determined. 
 
Setting 
 
The study was conducted in the Department of Cardiology, Christian Medical College Hospital, Vellore. 
The study was conducted during a 13 month period from November 2011 to November 2012. The 
patients with angina and normal epicardial coronaries in the coronary angiograms were consecutively 
enrolled for the study. Detailed history was obtained from each patient enrolled into the study. Detailed 
physical examination and coronary artery risk factor analysis performed for each patient. The coronary 
angiograms were cined at 30 frames per second. Informed consent was obtained from all enrolled 
patients. 
 
Subjects 
 
Inclusion Criteria 
1. Patients with angina and normal epicardial coronary arteries. 
2. Patients with structurally normal hearts 
3. Patients with normal left ventricular systolic functions 
4. Patients in sinus rhythm 
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Exclusion Criteria 
1. Patients with occlusive coronary arterial disease 
2. Patients with valvular heart diseases 
3. Patients with left ventricular systolic dysfunction 
4. Patients with cardiomyopathies 
5. Patients with pericardial diseases 
6. Patients with co-morbid conditions like renal failure, hepatic failure and significant pulmonary 
diseases 
7. Patients in atrial fibrillation 
8. Patients with unexplained left ventricular hypertrophy 
 
Study Protocol 
 
37 patients with angina and normal epicardial coronaries were enrolled for the study. Clinical and  
angiographic profile of the patients were studied in detail. 
 
Clinical Profile 
 
The clinical profile of all the patients were studied in detail. Detailed history was obtained from each 
patient. All of them had angina on presentation. The duration of angina was assessed for each patient  and 
its significance in coronary slow patients was determined. Other important aspects of history that has been 
taken into consideration include 
1. Associated symptoms like dyspnoea, palpitation and giddiness 
2. Hospitalizations in the past including that for chest pain/acute coronary syndromes 
3. History of allergy in the past 
4. History of asthma and its duration 
5. Past history of activity – athletic, body building, sedentary habits or yoga 
The presence or absence of the conventional coronary artery disease risk factors and duration of each was 
assessed in each patient. The association of the risk factors in coronary slow flow phenomenon(CSFP) 
was also determined. The various risk factors considered include 
1. Smoking 
2. Essential hypertension 
3. Diabetes mellitus 
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4. Dyslipidemia 
5. Obesity 
6. Sedantary activity 
The personality type of each candidate was assessed (Type A personality, nervousness, prone to anxiety 
or cool and casual attitude) and its association with CSFP was also determined. 
Baseline clinical characteristics like pulse rate, blood pressure, body mass index(BMI) were also assessed 
and their association with CSFP determined. Association of various biochemical parameters with CSFP 
was also determined. The biochemical parameters taken into consideration include hemoglobin, blood 
sugar, fasting cholesterol, LDL, HDL, LDL/HDL ratio, serum creatinine etc. ECG was obtained for each 
patient and looked for the presence of ST/T changes or voltage criteria for LVH. Echocardiography was 
done mandatory for all patients to rule out structural heart diseases, valvular heart diseases, 
cardiomyopathies and left ventricular systolic dysfunction.  Each patient was assessed for presence of 
LVH by echocardiography. Association of the ECG and echocardiographic features with CSFP was 
determined. 
 
Angiographic Profile 
 
All patients enrolled into the study underwent coronary angiogram by transradial route. We used 5F radial 
sheaths for the procedure and 5F TIG catheter was used for the selective coronary angiography. 
Controlled hand injections were used for the selective coronary angiography. All procedures were 
performed by a single operator who was a cardiology trainee. Iohexol (omnipaque) was the contrast used 
in all patients. 
 
Coronary angiography was performed by the transradial approach by the conventional techniques. 
Selective coronary angiography of the left and right coronary arteries were performed with the 5F TIG 
catheter. Angiographic images were cined at 30fps. Angiographic projections used for the analysis of 
LAD(Left anterior descending artery) were RAO cranial (RAO 10degrees and cranial 40 degrees) and 
LAO cranial (LAO 45degrees and cranial 20degrees) views. Angiographic projections for the analysis of 
RCA were RAO (30degrees) and LAO (45degrees) views. During acquisition, utmost care was taken for 
the proper visualization of the whole vascular territory. Long cineangiographic acquisitions were 
performed to visualize the contrast opacifying coronary artery ostium via distal standard vascular 
landmark to the coronary sinus ostium. Additional coronary acquisitions were acquired at the discretion 
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of the primary operator and consultant cardiologist. The additional acquisitions were cined at 15fps. The 
patient was hemodynamically monitored throughout the procedure. Assessment of the angiographic 
images was performed by the primary operator and consultant cardiologist. Coronary arterial filling and 
emptying times at prespecified landmarks were determined. Capillary and venous transit time and total 
transit time via the coronary vascular bed were also determined. The predictability of the above timings 
for CSFP was determined. The association of various clinical, physical and biochemical parameters with 
CSFP was also determined. 
 
Assessment of coronary arterial filling and emptying times 
 
Coronary flow is determined by the number of TIMI frame counts that the contrast takes to travel  
across the prespecified vascular landmarks. The landmarks for the TIMI frame count assessment  
of LAD are as follows 
 
A. Contrast opacifying the LAD ostium 
B. Contrast opacifying LAD at the origin of the major diagonal(D1 or D2 whichever is big) 
C. Contrast opacifying LAD at distal bifurcation 
D. Contrast opacifying the coronary sinus ostium 
E. Contrast fading off from the point B 
F. Contrast fading off from the  point C 
 
Similarly the angiographic landmarks for RCA are as follows 
 
A. Contrast opacifying the RCA ostium 
B. Contrast opacifying the RCA at the level of crux 
C. Contrast opacifying RCA at the origin of first posterolateral branch 
D. Contrast opacifying the coronary sinus ostium 
E. Contrast fading off from the point B 
F. Contrast fading off from the point C 
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The coronary filling and emptying times were determined based on these above points. The filling time is  
determined as the time of first frame of opacification at a predetermined proximal point to the first frame  
of opacification at a set distal point. Similarly emptying time is determined as the time of first frame of  
opacification at a predetermined point to the frame at which the contrast disappears completely. 
 
1. AB – Coronary filling time at point B. Time(Number of frame counts) taken for contrast to fill 
between points A and B. 
2. BC – Coronary filling time from B to C. Time (Number of frame counts)  taken for contrast to fill 
between points B and C. 
3. AC – Coronary filling time at point C. Time(Number of frame counts) taken for contrast to fill 
between points A and B. 
4. BB’ – Coronary emptying time at point B. Time(Number of frame counts) that the contrast takes 
to totally fade off from point B from the moment it get opacified. 
5. CC’ - Coronary emptying time at point C. Time(Number of frame counts) that the contrast takes 
to totally fade off from point C from the moment it get opacified. 
6. CD – Capillary and venous transit time. Time(Number of frame counts) taken for contrast to fill 
between points C and D. 
7. AD – Total coronary transit time. Time(Number of frame counts) taken for contrast to fill 
between points A and D. 
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Angiographic Landmarks for LAD and RCA – Pictorial Representation 
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Statistical Analysis 
 
Data was stored and and analyzed using SPSS version 17 (SPSS Inc. Chicago, IL, USA). Continuous 
variables are expressed as mean +/- standard deviation for normally distributed variables and median 
(inter-quartile range) for not normally distributed variables. Categorical variables expressed as number 
(percentage). Continuous variables were examined for normality of distribution using the Shapiro Wilk 
test. Differences in the frequency of the continuous variables were analysed using independent sample 
students t-test for normally distributed variables. For not normally distributed continuous variables a non-
parametric Mann Whitney test was used. For discrete variables, Chi square statistics (or Fischers exact 
test if applicable for a cell count less than 5) was used. Binary logistic regression analysis was used to 
identify the potential predictors of coronary slow flow phenomenon namely the coronary arterial 
fillingtimes, coronary arterial emptying times and coronary capillary and venous emptying times. All 
parameters that showed a p value less than 0.1 during initial analysis were included in the binary logistic 
regression analysis. A p value of less than 0.05 was considered statistically significant. 
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RESULTS 
 
Patients were enrolled into the study between November 2011 and November 2012. Among patients 
presenting with angina, who underwent coronary angiogram and found to have normal epicardial 
coronaries,  37 patients were selected consecutively based on inclusion and exclusion criteria. Among 
these patients flow in left anterior descending artery (LAD) and right coronary artery (RCA) were studied.  
Slow flow was ascertained on the basis of TIMI frame counts. TIMI frame counts more than 39 for the 
contrast to travel from LAD ostium to distal bifurcation for LAD and more than 24 for the contrast to 
travel from RCA ostium to first posterolateral branch was designed coronary slow flow in LAD and RCA 
respectively. On this basis we got 27 slow flow cases in LAD and 17 slow flow cases in RCA. Normal 
flow on the basis was seen in 10 cases in LAD and 12 cases in RCA. 8 patients had small dominant RCA 
and was excluded from the analysis. 
Figure 1: Study design 
 
 
 
 
 
 
 
 
 
 
Baseline Characteristics  
 
Baseline clinical characteristics are given in Table 1 and 2. The continuous variables considered include 
age, pulse rate, body mass index, systolic and diastolic blood pressures, hemoglobin, blood sugars, 
HbA1c, serum creatinine, lipid profile, LDL/HDL ratio etc. These variables were analysed in LAD slow 
flow group versus normal flow group and RCA slow flow group versus normal flow group. There was no 
RCA 29  LAD  37 
37 patients 
8 patients with non 
dominant small RCA ‐ 
excluded 
Slow Flow  27  Normal Flow 10  Slow Flow  17  Normal Flow 12 
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significant difference between the 2 groups with respect to most of the variables. The mean blood sugar, 
HbA1c, total cholesterol, LDL and triglyceride levels were more for the slow flow group of LAD as 
compared to the normal flow group, on the other hand the mean HDL level was less in the slow flow 
group compared to the normal flow group, but were not statistically significant. On the other hand, the 
LDL/HDL ratio was observed to be more in the LAD slow flow group and was found to be statistically 
significant. The mean hemoglobin level was observed to be significantly higher in LAD slow flow group 
as compared to the normal flow group. 
 
Table 1. Baseline characteristics of  Left System (LAD). 
Variable LAD Slow Flow 
Mean (SD) 
LAD Normal Flow 
Mean (SD) 
P value 
2 tailed 
Age 
 
51.4 (11.20) 54.5 (6.31) 0.378 
Pulse rate 
 
78.37 (12.80) 81.80 (7.08) 0.430 
BMI 
 
26.82 (3.22) 26.91 (5.05) 0.946 
SBP 
 
124.85 (18.09) 130.50 (22.45) 0.435 
DBP 
 
79.15 (9.66) 73.90 (14.79) 0.214 
Hb 
 
13.36 (1.51) 11.23 (1.91) 0.001 
AC 
 
123.44 (63.72) 113.22 (32.42) 0.649 
PC 
 
158.85 (75.72) 135.67 (59.20) 0.410 
HbA1c 
 
7.02 (1.92) 6.38 (1.08) 0.456 
S.creatinine 
 
1.10(0.19) 1.02(0.24) 0.293 
S. Cholesterol 
 
163.26(46.35) 144.30(37.37) 0.259 
LDL 
 
95.15(39.86) 85(36.40) 0.487 
HDL 
 
38.33(6.91) 49.9(17.72) 0.006 
LDL/HDL 
 
2.55(1.10) 1.58(0.64) 0.013 
TG 
 
164.93(78.03) 114.60(46.3) 0.065 
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LAD – Left anterior descending artery, SD – Standard Deviation, BMI – Body mass index, SBP and DBP 
– Systolic and diastolic blood pressure in mmHg, Hb – Hemoglobin in mg/dL, AC and PC – ante and post 
cibal blood sugars in mg/dL, TG – Triglycerides in mg/dL 
 
The continuous variables behaved in a similar fashion with respect to the right coronary artery also with 
some differences. The mean blood sugars and HbA1c levels were lesser in the slow flow group. Total 
cholesterol, LDL, LDL/HDL ratio and triglycerides were higher in the slow flow group but HDL levels 
were lower. However they were not statistically significant.  
 
Table 2.Baseline characteristics of RCA system. 
Variable RCA Slow Flow 
Mean (SD) 
RCA Normal Flow 
Mean (SD) 
P value 
2 tailed 
Age 
 
53.53 (10.80) 48.67 (10.44) 0.236 
Pulse rate 
 
76.12 (13.26) 81.33 (8.11) 0.237 
BMI 
 
27.44 (3.73) 26.21 (4.42) 0.428 
SBP 
 
124.18 (19.71) 122.17 (16.77) 0.777 
DBP 
 
77.82 (10.22) 75.67 (12.21) 0.610 
Hb 
 
13.15 (1.71) 11.87 (1.89) 0.066 
AC 
 
116.88 (40.78) 140.64 (89.34) 0.346 
PC 
 
152.53(67.29) 167.64(99.77) 0.635 
HbA1C 
 
7.07(1.68) 7.32(2.26) 0.800 
S.Creatinine 
 
1.12(0.16) 1.05(0.24) 0.355 
T. Cholesterol 
 
166.47(48.05) 143.17(30.55) 0.151 
LDL 
 
96.47(41.76) 84.25(30.04) 0.394 
HDL 
 
39.76(5.49) 47.17(17.79) 0.117 
LDL/HDL 
 
2.45(1.08) 1.88(0.96) 0.146 
TG 
 
164.82(77.56) 129.17(58.63) 0.191 
RCA – Right Coronary Artery 
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Baseline characteristics – categorical variables 
 
Table 3. Sex distribution in the slow and normal flow group in LAD 
 
 
   Coronary flow LAD 
Total 
 
   
Slow flow
Normal 
flow 
Sex  Male 20 3  
% (Coronary flow 
LAD) 
74.1% 30.0%
 
  Female 7 7 .023 
% (Coronary flow 
LAD) 
25.9% 70.0%
 
Total Count 27 10 37 
% (Coronary flow 
LAD) 
100.0% 100.0% 100.0% 
 
P-value 0.023 (2 sided), 0.020 (1 sided) 
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Table 4. Sex distribution in slow and normal flow group in RCA 
 
   Coronary Flow RCA 
Total 
   
Slow Flow
Normal 
Flow 
Sex  Male 14 5 19 
% (Coronary Flow 
RCA) 
82.4% 41.7% 65.5% 
 Female 3 7 10 
%  (Coronary Flow 
RCA) 
17.6% 58.3% 34.5% 
Total Count 17 12 29 
%  (Coronary Flow 
RCA) 
100.0% 100.0% 100.0% 
 
P value – 0.046 (2 sided), 0.030 (1 sided) 
 
Among the patients with slow flow observed in LAD, 74.1% were males and 25.9% females versus 30% 
and 70% among males and females respectively in patients with normal coronary flow. Similarly in 
patients with slow flow in RCA 82.4% were males and 17.6% females versus 41.7% and 58.3% in the 
normal flow group. This observation that coronary slow flow in LAD and RCA is more among males was 
statistically significant. 
Duration of angina was more than 1 month but less than 1 year in 63% of patients with slow flow in LAD 
and 58.8% of patients with slow flow in RCA (versus 30% in LAD normal flow and 50% RCA normal 
flow). The duration of angina more than one year, on the other hand, was observed in 33.3% of patients 
with LAD slow flow and 41.2% of patients with RCA slow flow (versus 70% in LAD normal flow and 
50% in RCA normal flow). Duration of angina less than one month was quite uncommon in slow flow 
population. Only 1 patient (3.7%) in LAD slow flow group had angina less than 1 month. 
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Other significant cardiac manifestations like dyspnoea, palpitation, giddiness etc were not common in the 
slow flow group. Dyspnoea was observed in 18.5% and 23.5% in LAD slow flow and RCA slow flow 
groups. When history of activity was considered, slow flow was observed to be more in those with 
sedentary life style. Among those with LAD slow flow 59.3% (30% in LAD normal flow) had sedentary 
life style and those with RCA slow flow 41.2% (versus 50% in RCA normal flow group) had sedentary 
life style.  
The distribution of the coronary artery risk factors in the slow flow group versus normal flow  
group is given in detail in the following tables separately for LAD and RCA. 
 
Table 5. Categorical variables distribution in LAD group 
 
Variable LAD SF(present) 
Number(%) 
LAD SF(absent) 
Number (%) 
LADNF(present) 
Number (%) 
LAD NF(absent) 
Number (%) 
Sex 
 
20(74.1) 7(25.9) 3(30) 7(70) 
Smoking 
 
6(22.2) 21(77.8) 0 10(100) 
Hypertension 
 
11(40.7) 16(59.3) 6(60) 4(40) 
Diabetes mellitus 
 
8(29.6) 19(70.4) 1(10) 9(90) 
Dyslipidemia 
 
4(14.8) 23(85.2) 1(10) 9(90) 
Obesity 
 
5(18.5) 22(81.5) 1(10) 9(90) 
Sedentary life style 
 
17(63) 10(37) 3(20) 7(20) 
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Table 6. Categorical variables distribution in RCA group 
 
Variable RCA SF(present) 
Number (%) 
RCA SF(absent) 
Number (%) 
 
RCA SF(present) 
Number (%) 
 
RCA NF(absent) 
Number (%) 
Sex 
 
14(82.4) 3(17.6) 5(14.7) 7(58.3) 
Smoking 
 
4(23.5) 13(76.5) 0 12(100) 
Hypertension 
 
10(58.8) 7(41.2) 3(25) 9(75) 
Diabetes Mellitus 5(29.4) 12(70.6) 4(33.3) 8(66.7) 
Dyslipidemia 
 
1(5.9) 16(94.1) 2(16.7) 10(83.3) 
Obesity 
 
4(23.5) 13(76.5) 1(8.3) 11(91.7) 
Sedentary life style 
 
7(41.2) 10(58.8) 7(58.3) 5(41.7) 
 
ECG changes (ST/T changes) were seen in 8 patients (29.6%) in LAD slow flow group and 4 patients 
(23.5%) in RCA slow flow group versus 3 patients (30%) in LAD normal flow group and 3 patients 
(25%) in RCA normal flow group. Treadmill test was done in 18 patients enrolled to assess the LAD flow 
among which 15 had slow flow and 3 had normal flow. Treadmill test was positive for inducible 
ischaemia in 8 patients with slow flow and 2 patients with normal flow. On the other hand, treadmill test 
was done in 14 patients enrolled for RCA flow study of which 8 had slow flow and 6 had normal flow. 
Treadmill test was positive in 3 slow flow patients and 4 normal flow patients. However we didn’t find 
any significant association of TMT positivity with slow flow phenomenon. 
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Angiographic Profile 
 
The coronary filling and emptying times at points B (diagonal for LAD and crux for RCA)  and C  (distal 
bifurcation for LAD and first posterolateral branch for RCA) were determined promptly by counting the 
number of TIMI frames that the contrast takes to transit between the predetermined points. Capillary and 
venous transit  time was determined by the number of TIMI frames the contrast takes to travel from C to 
D. Total transit time is determined by the TIMI frames the contrast takes to reach D from A.  
 
In short, AB and BB’ are the coronary filling and emptying times respectively at point B; AC and CC’ 
filling and emptying times at point C; CD capillary and venous transit time and AD total coronary transit 
time. These timings of LAD and RCA were studied separately. 
 
Angiographic Profile of LAD  
 
The correlation between the filling and emptying times at point B and C in slow flow and normal flow 
were studied first. The significance of these timings in the coronary slow flow population were analysed. 
Logistic regression for the former and students t-test for the latter were done. 
 
A positive correlation between AB and BB’ was observed which was statistically significant. The 
coefficient of correlation considering BB’ as the dependant variable to AB was 0.753. On the other hand 
there observed a negative correlation of BB’ with AB in patients with normal flow which was not 
statistically significant. 
A positive correlation between CC’ and AC in LAD slow flow group with coefficient of correlation 0.082 
for CC’ with AC was observed, but was not statistically significant. But same as at the point B, CC’ 
correlation with AC was negative and statistically insignificant for patients with LAD slow flow. 
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Table 7.Correlation of AB/BB’ – LAD slow 
flow  
LAD Slow Flow group 
 Mean Std. Deviation N 
BB’ 84.370 23.7352 27
AB 21.72 15.660 27
  
Correlations 
  BB’ AB 
Pearson Correlation BB’ 1.000 .497
AB .497 1.000
Sig. (1-tailed) BB’ . .004
AB .004 .
N BB’ 27 27
AB 27 27
LAD Slow Flow Group   
Coefficients 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 68.020 7.001  9.716 .000
AB .753 .263 .497 2.861 .008
Dependant variable BB’ 
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Table 8. Correlation of CC’/AC – LAD slow flow group 
LAD Slow Flow group 
 Mean Std. Deviation N 
CC’ 92.85 22.680 27
AC 77.944 32.6206 27
  
LAD – Slow Flow CC’/AC - Correlations 
  CC’ AC 
Pearson Correlation CC’ 1.000 .118
AC .118 1.000
Sig. (1-tailed) CC’ . .278
AC .278 .
N CC’ 27 27
AC 27 27
Coefficients 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 86.434 11.634  7.429 .000
AC_L .082 .138 .118 .596 .556
Dependant Variable CC’     
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Figure 2. Scatter plot showing the positive correlation of AB and BB’ in LAD slow flow patients 
 
 
Figure 3. Scatter plot showing non significant negative correlation of AB and BB’ in LAD normal 
flow patients 
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Figure 4. Scatter plot showing the positive correlation between AC and CC’ in LAD slow flow group 
 
 
 
The coronary arterial filling and emptying times at the origin of major diagonal and distal bifurcation are 
significantly prolonged in patients with coronary slow flow in LAD. The capillary and venous transit  
time on the other hand is found to be prolonged in slow flow patients but was not statistically significant. 
However the total transit time in LAD was significantly prolonged in slow flow patients.  
 
The association of various clinical and biochemical parameters with the coronary flow (ie, association 
with respect to the coronary arterial filling and emptying times) was also analysed.  Patients who 
presented to us with angina of duration one month to one year had prolonged filling times, emptying 
times, capillary and venous transit  times and total transit times as compared with those who present with 
angina of more than one year duration. However this association was not statistically significant. 
 
Males were found to have statistically significant prolonged coronary filling and emptying times and total 
transit times compared to females. The capillary and venous transit  times were also prolonged but was 
not statistically significant. Smokers had prolonged filling times, emptying times and total transit times 
but the capillary and venous transit times were found to be less compared to non smokers, with no 
statistical significance. Hypertensives were found to have less filling times, emptying times, total transit 
time and capillary and venous emptying times compared to normotensives without statistical significance. 
Diabetics on the other hand were found to have prolonged timings without statistical significance. The 
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correlation of these timings with pulse rate, blood pressure, BMI and various biochemical parameters like 
Hb, blood sugars, total cholesterol, LDL and HDL were assessed. Variable association of the various 
timings with these parameters which was not significant statistically was observed. LDL/HDL ratio and 
triglycerides positively correlated to all the timings and was statistically significant. 
 
Table 9. Association of the various LAD flow timings and its significance in CSFP 
Association of various framecounts& significance in LAD slow flow  
 Variabl
e N Mean Std. Deviation Std. Error Mean
P Value – 2 
tailed 
AB SF 27 21.72 15.660 3.014 0.009
NF 10 7.75 2.324 .735 0.000
BB’ SF 27 84.370 23.7352 4.5678 0.001
NF 10 52.550 19.8696 6.2833 0.001
AC SF 27 77.944 32.6206 6.2778 0.000
NF 10 34.900 5.2324 1.6546 0.000
CC’ SF 27 92.85 22.680 4.365 0.003
NF 10 68.80 12.669 4.006 0.000
CD SF 27 135.93 35.402 6.813 0.434
NF 10 125.90 30.598 9.676 0.408
AD SF 27 210.167 58.2097 11.2025 0.013
NF 10 159.900 26.9730 8.5296 0.001
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Angiographic Profile of RCA 
 
Similar to the LAD system the correlation between the coronary arterial filling and emptying times at B 
(crux of RCA) and C (first posterolateral branch) of RCA was assessed. A positive correlation of 
coronary emptying times at both points, namely BB’ and CC’ with the filling times, namely AB and AC, 
was observed in slow flow patients but was not statistically significant. On the other hand in normal flow 
group the correlation was negative but without statistical significance. 
 
In RCA the coronary arterial filling and emptying times at the level of crux and first posterolateral branch 
was observed to be significantly prolonged in coronary slow flow patients. Contrary to the LAD, RCA 
slow flow groups showed significant prolongation of the capillary and venous transit  times also. The total 
transit time was also significantly prolonged in RCA slow flow patients. The association of the various 
timings with the clinical and biochemical parameters were variable and non significant in RCA slow flow 
patients.  
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Figure 5. Scatter plot showing the correlation between AB and BB’ in the RCA slow flow patients 
 
 
Figure 6. Scatterplot showing correlation between AC and CC’ in RCA slow flow patients 
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Table 10. Association of the various RCA flow timings and its significance in CSFP 
 
Association of various framecounts& significance in RCA slow flow 
 
 Variabl
e N Mean Std. Deviation Std. Error Mean
P Value – 2 
tailed 
AB SF 17 30.41 9.296 2.255 0.000
NF 12 17.04 2.261 .653 0.000
BC SF 17 6.50 2.411 .585 0.058
NF 12 5.04 .940 .271 0.034
AC SF 17 36.91 10.135 2.458 0.000
NF 12 22.08 1.794 .518 0.000
CD SF 17 228.765 62.3992 15.1340 0.044
NF 12 188.125 27.4840 7.9339 0.026
BB’ SF 17 112.706 17.5598 4.2589 0.002
NF 12 92.542 13.4628 3.8864 0.002
CC’ SF 17 120.82 16.969 4.116 0.045
NF 12 107.58 16.232 4.686 0.044
AD SF 17 265.676 68.3257 16.5714 0.013
NF 12 210.333 27.5172 7.9435 0.006
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DISCUSSION 
 
Angina with normal epicardial coronaries occurs in upto 20% of patients who underwent coronary 
angiogram for angina. Coronary slow flow comprises a separate group among this population designed 
Syndrome Y and accounts for upto 7% of patients undergoing CAG for angina. Coronary slow flow 
phenomenon may manifest with unstable angina and acute coronary syndromes. It has been associated 
with  clinical manifestations of myocardial ischaemia, life threatening arrhythmias and even sudden 
cardiac death.Coronary slow flow has already been defined as the delayed passage of the contrast through 
the coronary vascular bed. The delay however is not at the level of epicardial coronaries but mainly at the 
microvascular level.  
 
John F Beltrame in many of his articles established the importance of microvascular tone in coronary 
slow flow patients. He suggested that the microvascular tone is elevated in patients with coronary slow 
flow even if the symptoms are quiescent. Coronary syndrome X is common in post menopausal women, 
on the other hand syndrome Y or coronary slow flow is commonly seen in young male smokers(3). Saya 
et al (7) described the occurrence of life threatening arrhythmias and sudden cardiac death in these 
patients. All these observations point towards the non de novo nature of syndrome Y unlike syndrome X. 
 
Conventionally slow flow is being determined by the delay in coronary filling. But the real pathology in 
coronary slow flow resides in the microvasculature. Hence we hypothesized that coronary arterial 
emptying time is a better predictor of slow flow phenomenon. We also aimed at capillary and venous 
emptying time and its association and significance in coronary slow flow patients. We also analysed the 
clinical and biochemical profile of these patients. Finally, the association of various clinical and 
biochemical parameters with the TIMI frame counts was also analysed. 
 
Our study showed significant prolongation of coronary emptying times in LAD and RCA in coronary 
slow flow patients, though slow flow may not be present in both arteries simultaneously. The previous 
studies looked into the coronary arterial filling times mainly for the determination of coronary slow flow. 
The coronary filling time determination is biased by lots of confounding variables like speed of injection, 
heart rate, operator dependant variables etc.  However coronary emptying time is non dependant on these 
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variables. Hence coronary emptying time may be considered to assess coronary slow flow in such 
circumstances.  
 
The association of capillary and venous transit  times in patients with CSFP was also analysed. We found 
the same to be significantly prolonged in patients with slow flow in RCA but prolonged in LAD but not 
statistically significant. The significance of the prolonged capillary and venous transit  time may be 
related to the single arterial system on the right side. The non significance of the capillary and venous 
emptying time of LAD may be related to the  
1. Confounding influence of the LCx flow. 
2. Variable degrees of the capillary branchings  
3. Non predictable venous diameters and tributaries 
 
A positive correlation between the coronary filling and emptying times in coronary slow flow patients 
was observed, but there was a negative correlation in patients with normal flow. This may be due to the 
delayed passage of the blood through the coronary microvascular bed in coronary slow flow patients. 
 
Coronary slow flow was observed to be significantly more in the males. Coronary flow as assessed by 
TIMI frame counts was observed to be significantly more in the male population. Coronary slow flow 
was observed to be more in smokers and the coronary flow filling and emptying times are prolonged in 
smokers, but there was no statistical significance. No  significant association of hypertension or diabetes 
was observed with coronary slow flow. The coronary filling and emptying times were found to be 
prolonged in diabetics and shortened in hypertensives, however was not statistically significant. This may 
be a pointer towards the increased incidence of microvascular dysfunction in diabetic population. 
 
No significant association of coronary slow with obesity was observed. Coronary slow flow was more in 
patients with sedentary lifestyle, also prolonged coronary filling and emptying times. No significant 
correlation was observed between total cholesterol, LDL cholesterol and HDL cholesterol in coronary 
slow flow patients. Significant association of CSFP in patients with high LDL/HDL ratio and 
triglycerides was observed . The coronary filling and emptying times were observed to be prolonged in 
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subjects with high LDL/HDL ratio and high triglycerides. The association was more in patients observed 
with LAD slow flow. 
 
To conclude, Coronary Emptying Time was found to be an independent predictor of coronary slow flow.  
In circumstances where coronary filling is subjected to multiple confounding factors, as listed above, 
Coronary Emptying Time remains independant of them and can be utilized as a predictor of CSFP. 
Capillary and venous transit time is prolonged in LAD and RCA slow flow but was significantly 
prolonged in RCA slow flow group alone.  CSFP is more in males and who were current smokers. CSFP 
as well as prolonged coronary filling and emptying times were  more in patients with increased LDL/HDL 
ratio. CSFP was seen more in patients with sedentary life style. However, further studies with more  
sample size may be required to substantiate our observations. 
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LIMITATIONS 
 
1. The vasodilatory response of various agents like calcium channel blockers, adenosine, NO, 
mibefradil has not been done .  Ideally the coronary filling and emptying times to be reassessed 
after the vasodilators. 
 
2. 27 slow flow and 10 normal flow patients in the LAD group and 17 slow flow and 12 normal 
flow in the RCA group were enrolled. The lesser number in the control arm might had 
confounding influences. Increased sample size would have provided better results 
 
3. Controlled hand injections to fill up the coronary bed with the contrast was utilized that was 
likely to have confounding influences on the filling time assessment 
 
4. Angiogram was performed by different operators and hence operator dependant factors might had 
a confounding influence 
 
5. The vascular landmarks mainly the point B (diagonal origin for LAD and crux for RCA) was 
arbitrary and varies among the populations.  
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CONCLUSIONS 
 
1. In addition to coronary artery filling times, Coronary artery emptying time  is an independent and 
significant predictor of coronary slow flow phenomenon.  
 
2. Capillary and venous transit time is significantly prolonged in patients with slow flow in RCA 
whereas in patients with LAD slow flow there is non significant prolongation of capillary and 
venous transit time. 
 
3. There is a positive correlation of coronary emptying time with coronary filling time in Coronary 
Slow Flow . This correlation is not seen  in patients with normal coronary flow. 
 
4. Coronary slow flow is observed significantly more in male population. 
 
5. Coronary slow flow is significantly associated with high LDL/HDL ratios and triglyceride levels 
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STUDY PROFORMA 
CLINICAL AND ANGIOGRAPHIC PROFILE OF PATIENTS WITH ANGINA  AND NORMAL 
EPICARDIAL CORONARIES 
 
Name:  
Age: 
Sex: 
Hospital Number: 
Occupation: 
Address: 
 
Phone number: 
CLINICAL PROFILE 
1)Chestpain – location – central/precordium/right side/whole chest 
 
           - type – heaviness/squeezing/pinpricking/burning 
       - radiation – left arm/right arm/jaw/throat/back 
      - associated sweating 
     - nature- continuous/intermittent                        
       2)Duration –    one month or less 
                                one month to one year 
 
         more than one year 
 
     3)other symptoms –  
 
Dyspnoea yes no 
Palpitations Yes No 
Giddiness Yes No 
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4)Any hospitalizations in the past – yes/no 
For ACS others 
 
5)History of allergy in the past – yes/no 
    Allergen –  
6)History of asthma – yes/no 
                                 - duration 
7)Past history of activity – athletic past 
                                        - bodybuilding 
                                         - yoga 
                                         - sedantary 
8)Risk Factors 
                                                         
   Duration(years) 
Smoking  Yes No  
Essential 
Hypertension 
Yes No  
Diabetes mellitus Yes No  
Dyslipidaemia Yes No  
Obesity Yes No  
Sedentary life 
style 
Yes No  
Oral contracptive 
intake 
Yes No  
Hormone 
replacement  
Yes No  
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9)Personality type  – Type A personality 
                               - prone to anxiety 
                            - nervousness 
                                - cool and casual attitude 
10) ECG features –  
ST/T changes Yes No 
LVH SV1+RV6 
>35 
Yes No 
 
11)ECHO features –  
LVPW : 
IVS: 
Mitral E/A: 
LVEF: 
LVH Yes No 
RWMA Present Absent 
Systolic 
dysfunction 
Present Absent 
Diastolic 
dysfunction 
Present Absent 
 
12)TMT features 
Effort tolerance Good Moderate Poor 
Response Positive Negative Equivocal 
Positive (if) Stage 1 Stage 2 Stage 3 
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13)Baseline clinical characteristics 
Pulse Rate –  
Blood Pressure – 
Height -                                
Weight -  
BMI –  
Built – lean/muscular/athletic/obese 
14)Blood Investigations 
AC -                                            
PC -                                     
HbA1c –  
S. Creatinine -  
Fasting Lipid Profile : 
Serum Cholesterol -  
LDL -                          
HDL -   
VLDL -                        
TG –  
LDL/HDL ratio -                         
Extra Notes: 
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ANGIOGRAPHIC PROFILE 
TIMI frame count in LAD 
 
 
 
 
 
 
 
 
 
 
 
TIMI frame count in RCA 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters LAD–LAO  LAD–RAO  
AB   
BC   
AC   
CD   
BB’   
CC’   
AD   
Parameters RCA–LAO  RCA–RAO  
AB   
BC   
AC   
CD   
BB’   
CC’   
AD   
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Angiographic landmarks for the TIMI frame count assessment of LAD 
A. Dye filling to the ostium of LAD 
B. Dye filling to the LAD at the origin of D2 
C. Dye filling to the LAD at distal bifurcation 
D. Dye filling to the ostium of coronary sinus 
B’. Dye emptying totally from point B  
C’. Dye emptying totally from point C 
AB – Coronary filling time to D2  
BC – Coronary filling time to LAD distal bifurcation 
CD – Capillary and venous  transit time 
AC- Total filling time of LAD 
AD – Total transit time AC+CD 
BB’ – Emptying time of LAD at D2 level 
CC’ -  Emptying time at LAD distal bifurcation 
 
Angiographic landmarks for the TIMI frame count assessment of RCA 
A. Dye filling to the ostium of RCA 
B. Dye filling to the crux of RCA 
C. Dye filling to the first branch of posterolateral artery 
D. Dye filling to the ostium of coronary sinus 
B’. Dye emptying totally from point B  
C’. Dye emptying totally from point C 
AB – Coronary filling time to PDA 
BC – Coronary filling time to distal bifurcation of RCA 
CD – Venous and capillary transit time 
AC- Total filling time of RCA 
AD – Total transit time AC+CD 
BB’ – Emptying time of RCA at origin of PDA 
CC’ -  Emptying time at distal bifurcation of RCA 
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CONSENT FORM 
Study Title: Clinical and Angiographic profile of patients with angina and normal epicardial 
coronaries 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
1. Declare that I have read the information sheet provide to me regarding this study and have clarified any 
doubts that I had. [ ] 
2. I also understand that my participation in this study is entirely voluntary and that I am free to withdraw 
permission to continue to participate at any time without affecting my usual treatment or my legal rights [ 
] 
3. I understand that I will receive free treatment for any study related injury or adverse event but I will not 
receive and other financial compensation [ ] 
4. I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this access [ ]  
5. I understand that my identity will not be revealed in any information released to third parties or 
published [ ]   
6. I voluntarily agree to take part in this study [ ] 
Name: 
Signature: 
Date: 
Name of witness: 
Relation to participant:                                                             Date:  
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INFORMATION SHEET 
CLINICAL AND ANGIOGRAPHIC PROFILE OF PATIENTS WITH ANGINA AND NORMAL 
EPICARDIAL CORONARIES 
1. This study is for research purpose and to study the clinical and angiographic profile of patients 
with chestpain and normal coronaries 
2. Expected duration : 1 year 
3. Description of the procedures – This is an observational study. We are not doing any extra 
procedures. In patients with chestpain if coronary angiogram shows normal coronaries we are 
trying to study the flow in coronary arteries and look for any slow flow in the coronaries that can 
contribute to the chestpain 
4. No foreseeable risks or discomforts to the subject 
5. No direct benefit to the subject 
6. No alternative procedures available to the subject 
7. Complete confidentiality of records identifying the subject will be maintained by Principal 
Investigator 
8. No compensation available to the subject in the event of a study – related injury 
9. Contact person the principal investigator for queries  
10. No anticipated prorated payment to the subject 
11. No subjects responsibilities on participation 
12. Subject’s participation is voluntary, that the subject can withdraw from the study at any time and 
that refusal to participate will not involve any penalty or loss of benefits to which the subject is 
otherwise entitled 
13. No apparent foreseeable circumstances under which the subject’s participation may be terminated 
by the investigator without the subject’s content. 
14. No additional costs to the subject that may result from participation in the study 
15. Subject can withdraw from the research and procedures at any time of study 
16. There will be no consequences on subjects decision to withdraw from the research 
17. Subject or subject’s representative will be notified in a timely manner if significant new findings 
develop during the course of the research which may be affect the subject’s willingness to 
continue participation will be provided 
18. We are not involving pregnant women in our study 
19. Approximate number of subjects enrolled in the study – 40 patients 
 
 
 
  
 
 
 
97 
 
GLOSSARY OF MASTER CHART 
CLINICAL AND ANGIOGRAPHIC PROFILE OF PATIENTS WITH ANGINA  AND NORMAL 
EPICARDIAL CORONARIES 
 
Name:  
Age: 
Sex: 
Hospital Number: 
Occupation: 
Address: 
 
Phone number: 
CLINICAL PROFILE 
1)Chestpain – location – central/precordium/right side/whole chest 
 
           - type – heaviness/squeezing/pinpricking/burning 
       - radiation – left arm/right arm/jaw/throat/back 
      - associated sweating 
     - nature- continuous/intermittent                        
       2)Duration –    one month or less    (1) 
                                one month to one year (2) 
 
         more than one year (3) 
 
     3)other symptoms –  0- no symptoms 
 
Dyspnoea Yes(1) no 
Palpitations Yes(2) No 
Giddiness Yes(3) No 
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4)Any hospitalizations in the past – yes(1)/no(0) 
For ACS others 
 
5)History of allergy in the past – yes(1)/no(0) 
    Allergen –  
6)History of asthma – yes(1)/no(0) 
                                 - duration 
7)Past history of activity – athletic past(3) 
                                        - Normal(1) 
                                         - yoga(4) 
                                         - sedentary(2) 
8)Risk Factors 
                                                         
   Duration(years) 
Smoking  Yes(1) No(0)  
Essential 
Hypertension 
Yes(1) No(0)  
Diabetes mellitus Yes(1) No(0)  
Dyslipidaemia Yes(1) No(0)  
Obesity Yes(1) No(0)  
Sedentary life 
style 
Yes(1) No(0)  
Oral contracptive 
intake 
Yes No  
Hormone 
replacement  
Yes No  
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9)Personality type  – Type A personality(1) 
                               - prone to anxiety(2) 
                            - nervousness(2) 
                                - cool and casual attitude(3) 
10) ECG features –  
ST/T changes Yes(1) No(0) 
LVH SV1+RV6 
>35 
Yes(1) No(0) 
 
11)ECHO features –  
LVPW : 
IVS: 
Mitral E/A: 
LVEF: 
LVH Yes(1) No(0) 
RWMA Present(1) Absent(0)
Systolic 
dysfunction 
Present(1) Absent(0)
Diastolic 
dysfunction 
Present(1) Absent(0)
 
12)TMT features 
Effort tolerance Good Moderate Poor 
Response Positive Negative Equivocal 
Positive (if) Stage 1 Stage 2 Stage 3 
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0 – Not Done 
1 – Positive 
2 - Negative 
 
13)Baseline clinical characteristics 
Pulse Rate –  
Blood Pressure – 
Height -                                
Weight -  
BMI –  
Built – lean/muscular/athletic/obese 
14)Blood Investigations 
AC -                                            
PC -                                     
HbA1c –  
S. Creatinine -  
Fasting Lipid Profile : 
Serum Cholesterol -  
LDL -                          
HDL -   
VLDL -                        
TG –  
LDL/HDL ratio -                         
Extra Notes: 
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Angiographic Profile 
 
NC_SF_L – Normal or slow flow LAD group 
 
1- Slow flow group 
 
2-  Normal flow group 
 
 
NC_SF_R – Normal or slow flow RCA group 
 
1- Slow flow RCA 
 
2- Normal flow RCA 
 
3- Non Dominant small RCA 
 
 
S.NO Name HospitalNoAge Sex Durationof Associated HospitalizaAllergy Asthma HistoryofacSmoking HypertensiDiabetesMDyslipidemObesity Sedantaryl
1 Patan Dalu 026072f 66 1 3 0 0 0 0 3 0 1 1 0 0 0
2 Mathura m071273f 69 1 2 0 0 0 0 3 0 0 1 0 0 0
3 Subhas Cha071092f 60 1 3 0 0 0 0 4 0 1 0 0 0 0
4 Swapan Bis072671f 44 1 2 1 0 0 0 2 0 0 0 0 1 1
5 Laxmi Kant069252f 52 1 3 1 0 0 0 3 1 1 0 0 0 0
6 Dilwara Be 048796f 50 2 3 0 0 0 0 2 0 0 1 0 0 1
7 Gopal Pras 078649f 44 1 2 0 0 0 0 2 0 0 0 0 0 1
8 Nazeema 430104a 54 2 2 2 0 0 0 1 0 0 1 1 0 1
9 Bidwattan  078545f 48 1 3 1 0 0 0 2 1 1 0 1 1 1
10 krishna Rao700956a 39 1 2 0 0 0 0 3 0 0 1 0 0 0
11 Anju Sinha 087212f 53 2 3 0 0 0 0 2 0 0 0 0 0 1
12 Ujjual Kum087213f 55 1 2 0 0 1 1 4 0 1 1 0 0 0
13 Dr. Devwra091803f 70 1 2 0 0 1 0 4 1 1 0 0 1 0
14 Manaf Ali 058726d 59 1 2 0 0 0 0 2 0 0 1 0 0 1
15 Balaram m101936f 32 1 2 2 0 0 0 2 0 0 0 0 0 1
16 Satyabham105673f 63 2 2 0 0 0 0 2 0 0 0 0 0 1
17 Zulaikha 124121c 39 2 2 2 0 0 0 2 0 0 1 1 0 1
18 Gopal V 098488f 43 1 2 0 0 0 0 2 0 0 0 0 0 1
19 Vivekanand991552d 40 1 3 1 0 0 0 2 1 1 0 1 1 1
20 Narendra P120471f 52 1 3 0 0 0 0 2 0 0 0 0 1 1
21 Rengaswam127274f 65 1 1 0 0 0 0 2 0 0 0 0 0 1
22 Rajenthiran243485f 55 1 2 0 0 0 0 2 1 1 0 0 0 1
23 Ashok Kum293018f 33 1 2 0 0 0 0 3 0 0 0 0 0 0
24 Suman Jais 307285f 52 2 2 0 0 0 0 2 0 1 0 0 0 1
25 Purnima Sa324066f 47 2 2 1 0 0 0 2 0 1 0 0 0 1
26 Kajal Kanti 435563b 53 1 2 0 0 0 0 2 1 1 0 0 0 1
27 Biswajit Ma260221f 29 1 2 0 0 0 0 3 0 0 0 0 0 0
28 Arati sarka 829535c 51 2 2 1 0 0 0 1 0 1 0 0 0 0
29 Sita Keriwa335709f 60 2 3 1 0 0 0 2 0 0 0 0 1 1
30 Atindra Na 302775f 56 1 3 0 0 0 0 1 0 1 0 0 0 0
31 Umesh Cha325535b 60 1 3 0 0 0 0 1 0 0 0 0 0 0
32 Lakshmi  295151c 44 2 2 3 0 0 0 1 0 0 0 0 0 0
33 Putul Mitra335771f 49 2 3 1 0 0 0 1 0 0 0 0 0 0
34 Parul Bala  296392f 63 2 3 0 0 0 0 1 0 1 0 0 0 0
35 Mandira Sh334140f 58 2 3 0 0 0 0 1 0 1 0 1 0 0
36 Sunaiana D343199f 59 2 3 1 0 0 0 1 0 1 0 0 0 0
37 Jiban Chan 268080c 56 1 3 0 0 0 0 2 0 1 1 0 0 1
Durationo DuratioPersonalitytype ECGchangeECG_LVH ECHO_LVHECHO_MitrTMT PR BP SBP DBP BMI Hb AC
2 1 2 1 1 0 60 160/80 22.83 16.2 256
1 2 0 0 0 0.84 2 60 110/80 24.24 12 98
10 2 0 0 0 1.4 0 80 140/80 27.12 12.9 131
2 1 1 1 0.71 1 90 120/90 25.78 14.9 111
5 2 0 0 1 0.66 0 80 130/90 27.05 14.2 80
14 2 1 0 0 0.64 0 90 110/80 26.31 11.8 386
2 1 0 0 1.1 0 84 100/70 24.3 14.3 99
0.5 2 0 0 0 1.2 1 70 140/90 27.63 12.6 100
8 2 1 0 1 0.48 2 108 148/86 28.23 15.2 122
1 2 0 0 0 0.84 2 60 110/80 24.24 13 159
2 0 0 0 0.64 2 90 110/80 26.31 10.4 100
15 2 2 0 0 0 0.68 2 70 110/80 29.76 14.3 115
1 1 0 0 0 0.49 0 70 104/60 31.93 11.9 109
5 2 0 1 0 1.1 0 84 100/70 24.3 13.5 128
2 0 0 0 0.96 2 80 120/80 23.23 13.4 104
2 0 0 0 1.1 1 78 130/80 24.46 11.3 102
2 2 0 0 0 1.2 0 76 140/90 27.63 12.9 182
2 0 0 0 0.76 1 70 110/70 25.6 14.8 93
3 2 1 0 1 0.48 2 108 148/86 28.23 13.8 117
2 0 0 0 1.5 1 82 130/80 37.13 12.6 98
2 1 0 1 1.15 0 76 140/80 23.51 14.2 95
10 2 0 0 1 0.78 1 80 150/100 23.31 15.6 86
2 0 0 0 1.86 0 62 92/55 27.03 14.7 92
2 2 0 0 1 1.3 0 82 130/80 31.99 10.5 101
2 2 1 1 1 1.2 0 88 154/96 30.56 12.9 102
3 2 0 0 0 0.78 1 78 120/68 28.23 13.8 89
2 1 0 0 1.1 1 88 110/70 24.9 14.1 95
1 2 0 0 1 0.88 0 80 150/88 25.7 10.9
2 0 0 1 0.72 0 96 140/80 38.45 9.9 108
23 2 0 0 1 0.63 1 78 110/70 25.79 10 97
2 0 0 0 1.2 0 70 98/50 19.68 8.7 98
2 1 0 0 1.7 1 78 128/70 23.68 12.9 82
2 1 0 0 0.83 0 78 108/64 28.3 12.1 105
4 2 0 0 0 1.1 2 84 148/92 23.53 9.3 119
4 2 0 0 1 0.81 0 86 159/69 28.15 10.8 113
12 2 0 0 1 1.4 0 60 149/82 28.8 11.7 85
1 4 2 0 0 1 0.63 0 80 110/60 25.3 14.8 195
PC HBA1C S_Creat T_Ch LDL HDL LDL_HDL TG NC_SF_L NC_SF_L_1AB_L BC_L AC_L CD_L BB_L
365 10.6 1.3 217 120 51 2.35 94 SF ‐ 1 1 11 42.5 53.5 113 86.5
163 7.1 1.3 208 114 41 2.78 265 SF ‐ 2 1 15.5 80 95.5 237 106.5
147 1.1 159 101 33 3.06 164 SF ‐ 3 1 27 29.5 56.5 98 68
162 1.2 138 82 36 2.27 112 SF ‐ 4 1 59.5 41 100.5 146 84
116 1.1 197 135 36 3.75 209 SF ‐ 5 1 17.5 46 63.5 123 84
403 11.4 1 218 142 34 4.17 210 SF ‐ 6 1 26.5 37.5 64 139 69.5
120 0.9 152 72 30 2.4 371 SF ‐ 7 1 49 120 169 131 152
145 6 0.8 136 69 44 1.57 82 SF ‐ 8 1 19 35 54 125.5 86
161 6.7 1.1 132 71 37 1.92 182 SF ‐ 9 1 42 45 82 101 87
155 8.3 0.8 264 177 42 4.21 246 SF ‐ 10 1 15.5 80 95.5 237 106.5
146 5.1 0.8 130 63 51 1.24 115 SF ‐ 11 1 26.5 37.5 64 139 69.5
122 5.4 1.1 140 77 41 1.88 128 SF ‐ 12 1 32 62 94 128 65
196 1.3 116 41 40 1 154 SF ‐ 13 1 17.5 75 92.5 153.5 102
247 7.9 1.2 220 150 35 4.29 174 SF ‐ 14 1 49 120 169 131 152
104 1.1 118 64 31 2.06 147 SF ‐ 15 1 13 34 47 112 74
152 0.8 116 57 32 1.78 153 SF ‐ 16 1 5 39 44 99.5 65
230 9.6 1 156 92 38 2.42 181 SF ‐ 17 1 12.5 33.5 46 133.5 92.5
103 1.2 244 167 48 3.48 101 SF ‐ 18 1 7 45 52 134 78
100 6.9 1.2 235 165 43 3.84 100 SF ‐ 19 1 32 62 94 128 65
116 1.01 108 47 42 1.12 80 SF ‐ 20 1 12 43.5 55.5 150 74.5
161 5.7 1.27 127 82 27 3.04 48 SF ‐ 21 1 7 53.5 60.5 187.5 70
128 5.7 1.53 207 129 27 4.78 347 SF ‐ 22 1 10 80.5 90.5 101 82.5
92 1.22 142 82 33 2.47 187 SF ‐ 23 1 47.5 65 112.5 144 97.5
117 5.8 1.28 143 62 49 1.26 203 SF ‐ 24 1 12 47 59 98 60
134 5.9 0.94 123 56 45 1.24 131 NC ‐ 1 2 5.5 23.5 29 112 81.5
153 5.4 1.1 125 68 42 1.62 128 SF ‐ 25 1 8 55 63 111.5 68.5
89 5.4 1.33 157 94 30 3.13 200 SF ‐ 26 1 4 63 67 135 74.5
115 0.96 170 95 59 1.61 110 NC ‐ 2 2 10.5 28.5 39 125.5 74.5
89 6.3 0.92 134 105 57 1.84 105 NC ‐ 3 2 6.5 20 27.5 120.5 18.5
83 1.68 112 54 40 1.35 81 NC ‐ 4 2 9 30 39 202.5 69.5
159 6.3 0.93 111 40 58 0.7 36 NC ‐ 5 2 7 32 39 104.5 64
1.05 121 68 32 1.12 76 NC ‐ 6 2 7 32 39 153 47
127 5.7 0.83 232 152 34 2.81 149 NC ‐ 7 2 5 34 39 111 54
126 1.06 163 101 40 2.52 115 NC ‐ 8 2 12.5 15 27.5 101.5 35
107 5.6 0.89 122 54 42 1.28 136 NC ‐ 9 2 6.5 25.5 32 109 36.5
96 6.3 0.8 103 46 42 1.09 72 SF ‐ 27 1 9 51 60 134 57.5
281 8.5 0.97 155 125 92 1.36 207 NC ‐ 10 2 8 30 38 119.5 45
CC_L AD_L NC_SF_R NC_SF_R_1AB_R BC_R AC_R CD_R BB_R CC_R AD_R
78 166.5 SF ‐ 1 1 21 6 27 163.5 113.5 114 190.5
136.5 332.5 SF ‐ 2 1 25.5 6.5 32 333 110.5 131 365
69 154.5 SF ‐ 3 1 20.5 6 26.5 148.5 87 90 175
95 246.5 SF ‐ 4 1 29 5.5 34.5 225.5 141 146 260
107 186.5 SF ‐ 5 1 25.5 4.5 30 205.5 122 126 235.5
74 203 NC ‐ 1 2 18 5 23 221 109.5 115.5 244
89 300 SF ‐ 6 1 44 10.5 54.5 307.5 132 137.5 362
89.5 179.5 NC ‐ 2 2 15.5 5 20.5 213 81.5 91 233.5
76.5 183
136.5 332.5 SF ‐ 7 1 25.5 7.5 33 332 110.5 116 365
74 203 NC ‐ 3 2 18 4.5 22.5 221.5 109.5 117.5 244
91.5 222 SF ‐ 8 1 40.5 6.5 47 228.5 108 113.5 275.5
74.5 246 SF ‐ 9 1 49 8.5 57.5 273.5 110 115 331
89 300 SF ‐ 10 1 44 7.5 51.5 310.5 132 139.5 362
95 159 NC ‐ 4 2 14 6 20 170 104 109.5 190
69 143.5
97.5 179.5 NC ‐ 5 2 15.5 5 20.5 190 82.5 95 210.5
111.5 86
91.5 222 SF ‐ 11 1 40.5 4.5 45 230.5 108 116.5 275.5
121 205.5 SF ‐ 12 1 27 3.5 30.5 226 133.5 140 256.5
137.5 248
92.5 191.5
107 256.5 SF ‐ 13 1 24.5 4 28.5 157.5 82 91.5 186
63.5 157 SF ‐ 14 1 23.5 4.5 28 225.5 119.5 125 253.5
85.5 141
88 174.5 SF ‐ 15 1 20.5 12.5 33 190.5 125.5 140.5 223.5
107 202 NC ‐ 6 2 19 3.5 22.5 164.5 86 99 187
79 164.5 NC ‐ 7 2 19 5 24 186.5 92 104.5 211
82.5 148 NC ‐ 8 2 20 4 24 152 67 83.5 177
71.5 217 NC ‐ 9 2 16.5 6.5 23 228 105.5 141 251
72.5 146.5 NC ‐ 10 2 18.5 4 22.5 192.5 99 117.5 215
76 195.5 NC ‐ 11 2 12.5 6 18.5 162.5 94 123 181
62 157
54 129 SF ‐ 16 1 27.5 4.5 32 159.5 92.5 103 191.5
51 141
46 194 SF ‐ 17 1 29 8 37 171.5 88.5 109 208.5
54 159.5 NC ‐ 12 2 18 6 24 156 80 94 180
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ABSTRACT Background: Angina with normal epicardial coronaries occurs in upto 20% of patients
who underwent coronary angiogram for angina. Coronary slow flow comprises a separate group
among this population designed Syndrome Y and accounts for upto 7% of patients undergoing CAG
for angina. Coronary slow flow is characterized by the delayed passage of contrast injected into the
epicardial coronaries. Conventionally, coronary slow flow is determined by the coronary filling time.
We tried to determine whether coronary emptying time is a significant predictor of coronary slow flow
Methods: We selected patients, who underwent angiogram for angina and found to have normal
epicardial coronaries,...
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